Allergist Video Statistics

Key takeaways

1. Allergists and allergy practices posting as themselves made 16.0% of the on-topic videos among YouTube’s most-viewed allergist, food allergy and allergy shots results and drew 2.4% of their views; patient and family story channels drew 39.7%. One doctor supplied 68.6% of the allergist views, and without him allergists drew 0.8% of the rest (our read, Nov 8, 2026). (Mark Studios) See details
2. Videos of 60 seconds or less drew 75.8% of those views. Titles about allergy shots or other immunotherapy were 24.5% of the 424 on-topic videos and drew 0.7% of the views, and no on-topic title named anaphylaxis, epinephrine or an auto-injector. (Mark Studios) See details
3. Across four peer-reviewed studies of allergy videos on social platforms published in 2026, the median share made by medical professionals was 42% (our calculation). Studies that counted misleading content found it in 16.6% to 36% of the videos sampled. (Mark Studios) See details
4. 3,274 allergists billed Medicare Part B fee-for-service in 2024, 3.3% fewer than the 3,385 in 2019; our ZIP code match puts 20 of them in Palm Beach County and 11 in Broward, and CMS’s file holds none in Martin. (CMS) See details
5. Medicare paid allergists $462.3 million ($462,273,793) in 2024, up 39.9% from $330.5 million ($330,454,645) in 2019 before inflation. Where CMS publishes the split, drugs went from 49.9% to 70.8% of those payments, while the median allergist’s payment rose 4.2% to $49,214 (our calculation). (CMS) See details
6. Medicare fee-for-service beneficiaries receiving skin-prick allergy tests in an office setting fell 21.5%, from 189,686 in 2019 to 148,903 in 2024, across all specialties, and those receiving two or more allergy shots fell 12.8%, from 152,603 to 133,066. These files leave out Medicare Advantage, so neither fall proves less care. (CMS) See details
7. The number of U.S. allergists depends on who counts: 7,282 diplomates on the American Board of Allergy and Immunology’s website, 6,126 active certificates at U.S. locations in the American Board of Medical Specialties’ June 30, 2026 count (296 of them in Florida), and 3,274 billing Medicare fee-for-service in 2024. BLS has no allergist occupation code. (ABAI, ABMS & CMS) See details
8. In the 2024 National Health Interview Survey, 31.7% of U.S. adults and 29.5% of children ages 0 to 17 had a diagnosed seasonal allergy, eczema or food allergy by their own or a parent’s report, and 6.7% of adults and 5.3% of children had a diagnosed food allergy. (NCHS) See details
9. Of 154 Form 10-K filings from 2001 to 2025 that contain the word allergist or allergists, 19 also contain “video”, and none of those describes a marketing, educational or training video (our count with EDGAR full-text search). (SEC) See details
10. The popular “50 million Americans” figure started in a 1997 NIH fact sheet as “as many as 40 to 50 million”, from a skin test survey. “1 in 13 children” rounds an 8.0% survey estimate published in 2011; the 2024 National Health Interview Survey found 5.3% with a diagnosed food allergy. (NIAID, Pediatrics & NCHS) See details

Who makes the most-viewed allergy videos on YouTube?

Allergists and allergy practices posting as themselves made 16.0% of the on-topic videos among the most-viewed videos YouTube returned for 'allergist', 'food allergy' and 'allergy shots' on November 8, 2026, and drew 2.4% of their lifetime views (our count). Patient and family story channels drew 39.7% of the views. This is one search on one date: we read YouTube’s own view-sorted results for those three terms on November 8, 2026, the first four pages for each, through the YouTube Data API with no country filter, and classified every channel by hand from its own title, description and video text.

The three lists held 509 unique videos from 349 channels, with 1,542,920,690 lifetime views in all, and 38 videos appeared in two or more lists. Most of those views had nothing to do with allergy care: channels we classed off-topic (songs titled Allergy, K-pop, ASMR roleplay, scripted skits, pranks, comedy sketches, game stories, veterinary allergy shots and generic injection clips) held 85 videos and drew 59.7% of the views. That left 424 on-topic videos from 279 channels with 622,419,431 views; the median one had 194,465.5 views. View counts are lifetime snapshots and include ad views.

27 allergist and allergy practice channels appeared in the November 8, 2026 sample. 17 of them said in their own text that they were allergists, immunologists or allergy specialists, and 10 gave only an allergy-practice name or practice text with no credential line; we did not check any licence or board certification. Group practices drew 0.6% of the on-topic views and individual allergists’ own channels drew 1.8%, almost all of that from one doctor: Dr. Zachary Rubin, a pediatric allergist and immunologist near Chicago, had 19 videos with 10,325,130 views, 1.7% of all on-topic views and 68.6% of the allergist class’s views. With him removed from both sides, allergists and practices drew 0.8% of the remaining on-topic views.

The most-viewed video from an allergist channel was Dr. Rubin’s 'DIY approach may have mixed results', with 2,489,218 views. Among practice channels, virtual allergy practice Wyndly Health’s 31-second 'GET RID OF ALLERGIC RHINITIS FOREVER!' led with 1,251,767 views.

Who else makes allergy videos?

Physicians of other specialties drew 5.6% of the on-topic views in our November 8, 2026 sample (our count), more than allergists did, with dermatologists, pediatricians and ENT doctors among them; skin allergy overlaps with our dermatology video statistics page. Homeopaths, ayurveda and siddha practitioners, naturopaths and chiropractors made 5.0% of the videos and drew 2.1% of the views, nearly as many views as allergists had. Pharmacists appear mostly in over-the-counter drug explainers; inhalers are covered on our pharmacy video statistics page.

Claritin’s two product videos drew 11.4% of the on-topic views, and view counts include any paid ad views. Medical animation drew 7.5% of the views from a handful of explainers, led by Zack D. Films’ 30-second skin-prick test short. Advocacy groups and professional associations, including FARE, the Allergy & Asthma Network, the American Academy of Allergy, Asthma & Immunology, the American College of Allergy, Asthma and Immunology and the American Medical Association, posted 2.6% of the videos and drew 0.1% of the views. We do not name the people or families behind patient and family story channels.

How much of this comes from a few channels?

The ten biggest channels drew 63.0% of the on-topic views in our November 8, 2026 sample (our count). The three biggest, one personal food-allergy channel, Claritin and Justice World, drew 37.9%, and that personal channel alone drew 18.1%. The most-viewed video was Justice World’s re-posted courtroom clip 'Man Sues Restaurant After NUT ALLERGY', with 52,495,134 views.

Where are the allergist channels based, and do Florida practices appear?

17 of the 27 allergist and allergy practice channels in our November 8, 2026 sample were placed in the United States (own text or channel country setting), and they posted 12.0% of the on-topic videos and drew 2.2% of the views (our count). 10 other allergist channels named a place outside the United States, most of them in India.

1 channel in the sample placed itself in Florida in its own text: Andrew Cooke, M.D. of Lake Allergy, Asthma & Immunology in Tavares, Lake County, whose one video had 686,163 views. 0 channels placed themselves in Palm Beach, Broward or Martin County in this search on this date; a channel can exist without appearing in a view-sorted sample.

What does each allergy search return?

Channels classed off-topic drew 72.8% of the views in YouTube’s most-viewed results for 'allergist' on November 8, 2026, mostly K-pop, ASMR and scripted shorts (our count), the noisiest of the three searches. In the 'food allergy' list, patient and family story channels drew 53.2% of the on-topic views. The 'allergy shots' list is the quietest, with a median of 15,667 views per on-topic video.

What are the most-viewed allergy videos about?

Titles about food allergy made 33.7% of the on-topic videos on November 8, 2026 and drew 46.9% of the views, while titles about allergy shots and other immunotherapy made 24.5% of the videos and drew only 0.7% of the views (our count, a regex on titles with every match read by hand).

0 of the 424 on-topic titles used the words anaphylaxis, epinephrine, EpiPen, auto-injector, Auvi-Q, neffy or adrenaline. Titles are a narrow read: a video can cover a reaction or a treatment without saying so in its title, and we counted only what titles say.

Videos of 60 seconds or less made 38.4% of the on-topic videos and drew 75.8% of the views, and the median short had 387,634 views against 140,717 for longer videos.

How often do U.S. allergist channels post?

The median U.S.-placed allergist channel posted 9 videos in the 365 days to November 8, 2026 (our count, every upload in the window read through the YouTube Data API that day). The 17 U.S.-placed allergist channels in our sample posted 1,826 videos in that year, but the spread is wide: 5 channels posted 100 or more videos and 7 posted none.

The three busiest posters, Dr. Zachary Rubin, Dr. Thomas Chacko and The Smartest Doctor in the Room, made 73.0% of the uploads. Dr. Rubin alone posted 781 videos, with a median of 32,300 views each. The median upload across all 17 channels had 3,850.5 views and 41.1% ran 60 seconds or less. In Florida, Lake Allergy’s channel in Tavares posted 0 videos in the year.

Do allergy videos carry YouTube’s synthetic-content label?

None of the 509 videos in our November 8, 2026 sample carried YouTube’s containsSyntheticMedia field, read through the YouTube Data API that day (our count); a field that is absent says nothing either way about how a video was made.

Who makes the allergy videos people find on YouTube and TikTok?

Medical professionals made less than half of them in most recent samples: across four peer-reviewed studies published in 2026 that reported a share from medical or health-care professionals, the median was 42% (our calculation), and the single samples ran from 33.3% to 58%. Each study sampled top results for one topic at one time and coded creators its own way, so the table gives each study’s date, platform, sample and finding side by side instead of one pooled figure. Quality scores use DISCERN (higher is better), modified DISCERN, the Global Quality Scale (GQS), the PEMAT understandability and actionability tool, or a scale built for that study.

How reliable are allergy videos on YouTube and TikTok?

Middling on the scales researchers use, with YouTube usually scoring above TikTok and Instagram: in Kwon et al.’s 2026 study of 460 short-form allergic rhinitis videos, YouTube Shorts averaged 3.12 on the Global Quality Scale against 2.21 on TikTok, and the authors found no platform on average was adequately actionable or completely accurate (Laryngoscope Investigative Otolaryngology). Lian et al. reported the same direction for YouTube against the Chinese platform Bilibili, with median modified DISCERN of 3 against 1 (BMC Public Health). The lowest score here covers a narrow topic: the June 2024 sample of TikToks on mast cell activation syndrome averaged 1.94 on a 1 to 5 range (Allergy and Asthma Proceedings).

Popularity and quality do not line up. In Kumar et al.’s 2025 analysis of 50 YouTube videos on allergic rhinitis management, DISCERN scores and views were negatively correlated at -0.42, and only 20% of the videos mentioned immunotherapy (Indian Journal of Otolaryngology and Head and Neck Surgery). In Yıldırım et al.’s April 2026 sample on cow’s milk protein allergy, non-medical creators drew significantly more engagement while medical creators scored higher on all three quality instruments (European Journal of Pediatrics). Toprak et al.’s auto-injector study, published online in February 2024, found no significant difference in views, likes, duration or upload time between health and non-health sources (European Annals of Allergy and Clinical Immunology).

How much allergy video content is wrong or misleading?

Between 16.6% and 36% of videos in the three studies that counted it: 16.6% of short-form videos on cow’s milk protein allergy in an April 2026 sample (European Journal of Pediatrics), 36% of 50 YouTube videos on allergic rhinitis management in a 2025 analysis (Indian Journal of Otolaryngology and Head and Neck Surgery), and 36% of 86 YouTube videos on allergic rhinitis in a 2022 study (Annals of Allergy, Asthma & Immunology). Each study set its own definition. In the 2022 study, videos from television shows and YouTube channels held 23.4% of total views and 48% of the misleading videos (Annals of Allergy, Asthma & Immunology).

One study went looking for misinformation on purpose, so its figures describe themes, not how common misinformation is. Khadija et al. analysed 347 allergy-misinformation posts with 500 or more interactions, from January to March 2025 on TikTok, Instagram, Facebook and X, with 12.3 million combined views. Natural cure promotion was the most common theme at 31%, followed by IgG testing endorsement at 24% (Journal of Allergy and Clinical Immunology: In Practice). Of 3,470 comments on those posts, 62% were supportive or neutral toward the misinformation, and only 23% of corrective comments included scientific evidence (Journal of Allergy and Clinical Immunology: In Practice).

Some parents act on what they see. In a questionnaire published in 2026, among parents of 200 children at a pediatric allergy clinic in Ankara, Turkey, 22% changed their child’s treatment based on social media, and 55% of those did so without consulting a physician (Turkish Archives of Pediatrics). That is one clinic and a self-report.

Does video training teach auto-injector technique?

The trials split: video matched routine teaching in one randomized trial and trailed face-to-face training in another. In Yuenyongviwat et al.’s 2020 trial of 129 medical students in Thailand learning an epinephrine prefilled syringe, 95.3% passed after video teaching against 96.6% after routine teaching, a difference that was not significant (Asia Pacific Allergy). In Fernandez-Mendez et al.’s 2017 randomized pilot of 50 laypeople in Spain, the face-to-face group recognised anaphylaxis better and faster and used the adrenaline injector with more precision and fewer mistakes than three video groups (BioMed Research International). Skills also faded. In a paper published in 2025, Močnik et al. retrained 15 venom-allergic patients in Slovenia by video 5 years after immunotherapy, and 80.0% lacked proficiency a month later (Acta Dermatovenerologica Alpina, Pannonica et Adriatica). The authors concluded video instruction alone may be insufficient. These are small studies in different groups of people, and none measured use in a real reaction.

Knowledge and confidence rose in the uncontrolled studies, but they measure what people say or know soon after watching, and the two device trials suggest the injector itself matters as much as the teaching. Reach can be the limit too: only 3.5% of the French teachers invited completed the survey around the video program.

Has anyone tested video before oral food challenges or allergy shots?

Not in a trial we could find: our PubMed searches returned no study of an educational video given before an oral food challenge or before allergy shots. The closest match is a consent study in oral immunotherapy in Ontario, Canada, published in 2020, in which 467 parents and patients older than 12 took tests around a counseling video in a checklist-based session and scored significantly better afterward (Annals of Allergy, Asthma & Immunology). The video was one part of a 2-hour session with no control group, and the first author is also listed at a pediatric allergy practice. Decision tools are thinly used as well: in a U.S. survey from November to December 2019 of 304 health care providers who treated nasal allergies, 67% of allergists reported not using an allergen immunotherapy shared decision-making tool, primarily because of unawareness (Allergy and Asthma Proceedings).

How does tele-allergy compare with in-person care?

Patients report similar satisfaction, and testing is the sticking point: in Mustafa et al.’s prospective study, published in 2021, of 447 encounters at one allergy/immunology practice during the COVID-19 pandemic, 21.9% were video and satisfaction was similar across in-person, video and telephone visits, though patients and physicians were more likely to deem an in-person encounter complete (Journal of Allergy and Clinical Immunology: In Practice). At an academic practice in San Francisco, environmental skin testing completion was 60% from March 10 to June 30, 2020, against 91% a year earlier, which is 31 percentage points lower (our calculation) (Journal of Allergy and Clinical Immunology: In Practice). That period was a pandemic shutdown, so the drop is not attributable to video visits alone. Most studies below are single-center and uncontrolled, and several date from the first months of the pandemic.

How many allergists are there in the United States?

The American Board of Medical Specialties (ABMS) counted 6,126 physicians with an active allergy and immunology certificate at U.S. locations as of June 30, 2026 (ABMS). That is one count of several, and the sources do not agree, because they count different people at different dates.

The ABAI website count sits 1,156 above the ABMS U.S. count and 1,588 above the registry count (our calculations). Those gaps are differences in definition, not errors to correct. A certificate count includes retired physicians. A registry count depends on the specialty code a provider selects. A specialty count depends on what a physician reports. The federal wage survey has no occupation code for allergists at all, so the workforce section of this page reports them only as part of all-other physicians.

The board's own page shows how much a definition moves a number. ABAI lists 1,443 diplomates who take part in Maintenance of Certification but are not meeting its requirements (ABAI). ABMS reports that 58.3% of allergy and immunology diplomates also hold a certificate from another ABMS board (ABMS), which fits a specialty entered through internal medicine or pediatrics. In AAMC's latest specialty table, 50.6% of active allergists were 55 or older in 2021 (AAMC).

How many allergists are there in Florida, and in Palm Beach, Broward and Martin counties?

ABMS recorded 296 physicians with an active allergy and immunology certificate at Florida locations as of June 30, 2026 (ABMS). Florida ranks fourth among the states, behind California with 770 (ABMS), New York with 530 (ABMS) and Texas with 443 (ABMS).

Florida held 4.8% of U.S. allergy and immunology diplomates and 5.9% of U.S. diplomates of all boards, counted as 59,378 in Florida (ABMS) and 1.0 million (1,011,180) nationally (ABMS). Both shares are our calculations. Certificates include retired physicians, so these figures do not measure who is seeing patients.

We found no Florida government count of allergists by county. The Florida Department of Health's 2025 Physician Workforce Annual Report covers 62,209 physicians who renewed a license between July 2023 and June 2025, answered its survey and provide direct patient care (Florida DOH). Its county tables list specialty groups, and allergy and immunology is not one of them in that edition. Its county totals for physicians of all specialties are 4,368 in Palm Beach (Florida DOH), 5,183 in Broward (Florida DOH) and 494 in Martin (Florida DOH). Those totals are not allergists.

How many new allergists are trained each year?

The Accreditation Council for Graduate Medical Education (ACGME) counted 342 active allergy and immunology fellows in academic year 2024-2025, in 92 accredited programs (ACGME). The fellow count is up 19.2% from 287 in 2015-2016 (ACGME), by our calculation. ACGME counted 166 graduates in academic year 2023-2024 (ACGME), and women were 64.9% of active fellows in 2024-2025 (ACGME). ABMS counted 174 new allergy and immunology specialty certificates in 2025 (ABMS).

The American Board of Allergy and Immunology's certification examination had 188 candidates in 2025 (ABAI), with a total pass rate of 93% (ABAI). First-time candidates passed at 97% (ABAI) and repeat candidates at 72% (ABAI). The total pass rate was at its 2016-2025 low of 81% in 2021, as it was in 2017 and 2018 (ABAI).

How hard is it to get an appointment with an allergist?

In a July to November 2025 telephone survey of 1,301 practice sites across the 12 U.S. Midwest states, 6.6% of practicing allergists offered an appointment within two weeks (King et al., Annals of Allergy, Asthma & Immunology, 2026). The survey identified 613 practicing allergists (King et al.), of whom 74.1% accepted Medicaid (King et al.). The mean distance to the nearest allergist was 83.6 miles (King et al.).

Nationally, Ho and colleagues (American Journal of Managed Care, 2024) found that 55.5% of the 5,694 allergists they checked accepted Medicaid (Ho et al.), with state rates running from 13% to 90% (Ho et al.). In a June to July 2024 phone survey and travel analysis of 49 asthma specialists in and around Maine, 18% of Maine children would need to travel more than an hour to reach an asthma specialist (Bohnhoff et al., Journal of Asthma and Allergy, 2025).

We found no national count of allergist wait times and no published study of waiting-list letters in U.S. allergy clinics (PubMed, searched November 8, 2026). The Midwest and Maine studies cover those regions only.

How many allergists use telehealth?

92% of allergy and immunology physicians who answered the American Medical Association's national telehealth survey said they currently used some form of telehealth, in a survey run from November 1 to December 31, 2021 (ACAAI, reporting AMA). Only 136 physicians answered as allergists (ACAAI), the sample was a convenience sample, and the American College of Allergy, Asthma & Immunology (ACAAI), an association of allergists, promoted it to its members. The AMA says the results are directional and do not generalize to the specialty (AMA). We found no more recent national figure for allergists.

Of the respondents who used telehealth, 97% held live audio and video visits (ACAAI, reporting AMA). Among those answering the question on practice type, 52% described a single-specialty physician office (AMA) and 24% a solo practice (AMA).

Two narrower association surveys point the same way. In an April to May 2022 survey of ACAAI members, 86% of the 138 responders who treat hereditary angioedema said they had used telehealth for appointments occasionally since the pandemic began (Meadows et al., Annals of Allergy, Asthma & Immunology, 2023). In April to May 2020, 95% of allergy and immunology fellows answering an American Academy of Allergy, Asthma & Immunology (AAAAI) survey had used telehealth; 124 of 380 fellows responded (Kahwash et al., Journal of Allergy and Clinical Immunology: In Practice, 2021). Studies of how well allergy telehealth works are in the evidence section of this page.

How many allergists offer allergy drops or oral immunotherapy?

73.5% of 268 U.S. respondents to an ACAAI member survey published in 2019 reported experience using sublingual immunotherapy, the under-the-tongue allergy treatment (Sivam et al., Annals of Allergy, Asthma & Immunology, 2019). In the same association's March 2007 survey, 5.9% of 766 U.S. allergists reported using it (Tucker et al., Annals of Allergy, Asthma & Immunology, 2008). The 2019 authors say FDA-approved products likely contributed to the rise. Both surveys sampled members who chose to reply.

50% of AAAAI members who answered a November 2021 survey offered food oral immunotherapy in their practice (Anagnostou et al., Journal of Allergy and Clinical Immunology: In Practice, 2023). Only 78 of the 780 members sampled replied, so the share may not hold for allergists as a whole. An earlier AAAAI member survey, published in 2015, found 13.8% of 442 respondents taking part in food oral immunotherapy, before any FDA-approved product existed (Greenhawt and Vickery, Journal of Allergy and Clinical Immunology: In Practice, 2015).

Shared decision-making tools were not widely used. In a November to December 2019 survey of 304 U.S. health care providers who treat nasal allergies, 67% of the allergists said they did not use a shared decision-making tool for allergy immunotherapy, mainly because they did not know about one (Winders et al., Allergy & Asthma Proceedings, 2021). One author was affiliated with ALK, which makes sublingual immunotherapy tablets, when the paper appeared.

Who owns allergy practices?

We found no public count of how many allergy practices private equity firms own. Deals are documented one at a time, mostly in press releases from the buyers and their advisers.

Waypoint Capital announced in December 2021 that an affiliate had bought a 70% stake in Allergy Partners, which it called the largest U.S. group of single-specialty allergy and asthma practices (Waypoint Capital). Allergy Partners had 135 physicians at the time (Waypoint Capital). The company now describes itself as 140 allergists and immunologists (Allergy Partners), equal to 2.3% of U.S. ABAI diplomates in the ABMS count (our calculation; the company's number is self-described). Family Allergy & Asthma, a portfolio company of the firm Prairie Capital, had more than 50 allergists in September 2021, according to the investment bank that advised a practice it bought (SC&H Capital).

FOCUS Investment Banking, which sells merger advice to specialty practices, counted 13 private equity-backed practice management companies in ear, nose and throat and allergy care in April 2024, and dated the first such investments to 2018 (FOCUS). It said most of them target ear, nose and throat groups and only a few focus on allergy, so that count is not a count of allergy groups.

How many allergy practices use video to reach patients?

No national survey of how allergy practices use video exists that we could find, either from an association or in the peer-reviewed literature (PubMed and association websites, searched November 8, 2026). The closest measures are indirect: the telehealth share above, where 97% of telehealth users held live video visits, and the counts of videos and channels in the YouTube section of this page. Any figure for how many allergy practices publish video, or what share of new patients find a practice through it, should be treated as unsupported unless its source can be read.

How many allergists bill Medicare?

CMS’s Medicare Physician & Other Practitioners file lists 3,274 allergists (provider type “Allergy/ Immunology”) who billed Medicare Part B fee-for-service in 2024 (CMS), against 3,385 in 2019 (CMS), a fall of 3.3% (our calculation). The file is built from original Medicare claims only. It leaves out Medicare Advantage and every patient outside Medicare, so an allergist who saw only those patients is not counted, and every count in this section understates the work as Medicare Advantage grows. CMS also does not publish records built on fewer than 11 beneficiaries: the smallest beneficiary count on any allergist row is 11 (our calculation). Provider type is the specialty CMS assigns from the claims.

Florida has 196 allergists in the 2024 file (CMS), down 8.0% from 213 in 2019 (CMS; our calculation). Florida holds 6.0% of the allergists billing Medicare Part B fee-for-service in the United States (our calculation), and only California, New York and Texas have more.

Most allergists in the file work in cities: 95.0% of those billing Medicare in 2024 have a practice address that CMS codes as a metropolitan core (RUCA 1) (our calculation from the CMS file).

How many allergists bill Medicare in Palm Beach, Broward and Martin counties?

20 allergists with a Palm Beach County practice address billed Medicare Part B fee-for-service in 2024, 11 in Broward County and 0 in Martin County, by our match of CMS’s by Provider file to the Census Bureau’s ZIP-to-county relationship file. The three counties hold 15.8% of Florida’s allergists in the file (our calculation).

These are not head counts of every allergist in those counties. An allergist who saw only Medicare Advantage or commercial patients, or 10 or fewer Medicare Part B fee-for-service beneficiaries, is not in the file, so an empty Martin County row means no allergist there cleared that bar in CMS’s data. A ZIP code split across counties goes to the county holding most of its land, and the only allergists in a ZIP shared with Martin County are Jupiter practices in 33458, which counts as Palm Beach County.

How much does Medicare pay allergists?

Medicare paid allergists $462.3 million (462,273,793) for Part B fee-for-service services in 2024, by our sum of CMS’s by Provider file. That is 39.9% more than the $330.5 million (330,454,645) it paid them in 2019, before inflation (our calculation). Florida’s allergists received $47.0 million (46,969,410) in 2024 (our calculation). The file cannot tell a change in care apart from patients moving to Medicare Advantage, whose claims it leaves out, and patients outside Medicare are not in it at all.

The rise is in drugs. On the rows of the file that publish the split, Medicare paid allergists at least $274.4 million for drugs in 2024 (274,421,909), up 107.5% from at least $132.3 million (132,273,070) in 2019, before inflation. Payments for medical services other than drugs fell 14.5% on those rows (our calculation). Drugs were 70.8% of payments on those rows in 2024 and 49.9% in 2019 (our calculation). CMS withholds the split for a provider when fewer than 11 beneficiaries had a drug service, so the drug totals are floors. Only drugs billed under Part B are in these files. A drug a patient picks up at a pharmacy under Medicare Part D is not.

The typical allergist’s Medicare total rose far less than the sum. The median allergist received $49,214 from Medicare Part B fee-for-service in 2024, up 4.2% from $47,247 in 2019, before inflation (our calculation). The median Florida allergist received $86,139 in 2024 (our calculation).

The money is concentrated. 54 allergists received $1 million or more from Medicare Part B fee-for-service in 2024, against 23 in 2019 (our calculation). 54 of the 2024 group received more than half of it for drugs (our calculation), which is all of them. The top 10% of allergists by payment received 55.5% of Medicare Part B payments to allergists in 2024, up from 47.9% in 2019 (our calculation).

A service in CMS’s file is a billed unit, not a visit. Allergists billed 25.5 million services (25,465,118) in 2024 and 21.2 million (21,247,501) in 2019 (our calculation). Each skin test, each antigen dose and each drug billing unit counts as a service, so neither total measures patients or visits. CMS also hides any provider-and-service line with fewer than 11 beneficiaries. The lines that remain hold 61.8% of the Medicare payments to allergists in CMS’s by Provider file, so totals by code in this section are floors (our calculation).

How many Medicare beneficiaries get allergy tests and allergy shots?

148,903 Medicare beneficiaries received percutaneous (skin-prick) allergy tests (CPT 95004) in office settings in 2024, across all specialties, in CMS’s by Geography and Service file (CMS). That is down 21.5% from 189,686 in 2019 (CMS; our calculation). The file counts Medicare Part B fee-for-service patients only, with no Medicare Advantage and no patients outside Medicare, so a fall can reflect patients moving to Medicare Advantage as well as less testing or fewer shots. Every code in the table fell.

Beneficiaries are the number to read for how many people. Service counts for these codes are inflated by the way CMS counts them. CPT 95004 is billed per test, so CMS lists 8.56 million services in office settings in 2024 (8,560,493.5) (CMS) and 10.54 million in 2019 (10,542,648.6) (CMS), which is 57.5 billed units per beneficiary in 2024 (our calculation). Intradermal testing (CPT 95024) shows 1.33 million services in 2024 (1,329,139) (CMS). Antigen preparation (CPT 95165) is billed per dose: 5.85 million services in 2024 (5,850,584.5) (CMS) and 7.59 million in 2019 (7,586,141) (CMS). None of these is a count of patients or of visits.

The payments per unit are small. The average Medicare payment per billed unit of CPT 95004 in office settings was $2.79 in 2024 (CMS) and $3.32 in 2019 (CMS), before inflation. For CPT 95117 it was $8.35 in 2024 (CMS), and for a dose of antigen under CPT 95165 it was $10.44 (CMS). These are all-specialty averages.

Allergists are not the only ones billing these codes. 8,719 providers of all specialties billed CPT 95004 in office settings in 2024 (CMS), and 2,088 allergists had a line for it covering 11 or more beneficiaries (CMS), against 2,383 in 2019 (CMS). 1,976 allergists had such a line for CPT 95117 (CMS) and 1,684 for CPT 95165 (CMS) in 2024. Allergists’ own published lines hold at least 55.5% of the office-setting services of CPT 95004, 61.0% of CPT 95117 and 52.5% of CPT 95165 in 2024 (our calculation). Those shares are floors, because an allergist with fewer than 11 beneficiaries for a code has no line. The rest sit with other specialties or on lines too small to publish.

In Florida, 14,430 beneficiaries received CPT 95004 in office settings in 2024 (CMS), down 26.0% from 19,501 in 2019 (CMS; our calculation). 11,230 received CPT 95117 in 2024 (CMS), down 18.3% from 13,744 in 2019 (CMS; our calculation). Both counts are all specialties, Medicare Part B fee-for-service only.

Which allergy and asthma biologics does Medicare Part B pay for?

Omalizumab (HCPCS J2357) reached 12,557 Medicare Part B fee-for-service beneficiaries in office settings in 2024, across all specialties, (CMS), up 21.7% from 10,319 in 2019 (CMS; our calculation). The table counts beneficiaries, because drug services are billing units that differ from one code to the next. Medicare Advantage patients and patients outside Medicare are not counted.

Omalizumab is billed per 5 mg, so its service count is a count of doses in small units: 7.27 million in office settings in 2024 (7,268,072) (CMS), at an average Medicare payment of $29.33 per unit (CMS). That comes to about $213.2 million (213,200,390) across all specialties (our calculation: billed units times the average payment). 4,582 providers of all specialties billed the code in office settings in 2024 (CMS).

On allergists’ own published lines, Medicare Part B fee-for-service paid $68.7 million for omalizumab in 2024 (68,674,726) and $44.3 million in 2019 (44,311,613), before inflation (our calculation). 333 allergists had an office-setting line for the drug in 2024 (CMS) and 223 in 2019 (CMS), each covering 11 or more beneficiaries. Those lines hold at least 32.2% of the office-setting billing units of the drug (our calculation), a floor for the same reason as above.

In Florida, 1,612 beneficiaries received omalizumab in office settings in 2024 (CMS), up 7.8% from 1,495 in 2019 (CMS; our calculation), across all specialties.

How much of allergists’ Medicare billing is office visits, and what do the files show about telehealth?

Office visits (CPT 99202-99205 and 99211-99215) were 4.1% of the billed services on allergists’ published lines in CMS’s 2024 provider-and-service file, against 5.5% in 2019 (our calculation). The share is low because each skin test, antigen dose and drug billing unit counts as a service. Set those units aside and office visits were 23.5% of billed services in 2024 (our calculation). In dollars, office visits were 22.1% of the Medicare payments on those lines in 2024 and 27.6% in 2019 (our calculation). All of this is Medicare Part B fee-for-service, on lines with 11 or more beneficiaries.

The public files say very little about video visits. Their columns carry no telehealth modifier, and the place-of-service field has only two values, office or facility, so a video visit billed under an office-visit code cannot be told apart from one in person. Two narrower signals exist. Allergists’ published lines held 2,378 audio-only telephone visits (CPT 99441-99443) in 2024, and the 2019 file has no published allergist line for those codes (our calculation). They also held 23 remote evaluations of recorded video or images from established patients (HCPCS G2010) in 2024 (our calculation). Lines covering fewer than 11 beneficiaries are suppressed, so both are floors, and neither counts telehealth paid by Medicare Advantage or by anyone outside Medicare.

How many physicians does BLS count in the all-other group that holds allergists?

The Bureau of Labor Statistics estimated 342,720 wage and salary jobs in Physicians, All Other (SOC 29-1229) in the U.S. in May 2025, in its Occupational Employment and Wage Statistics (OEWS) survey of employers (BLS). BLS has no occupation code for allergists and immunologists, so they are counted inside this catch-all for physician specialties without their own code. Every figure in this section describes all-other physicians as a group, never allergists alone, and BLS publishes nothing that separates allergists from the rest of the group. Counts of allergists themselves come from other sources on this page.

The Occupational Outlook Handbook, which also counts the self-employed, puts the group at about 367,400 U.S. jobs in 2025 (BLS). BLS’s Employment Projections put the self-employed share of those jobs at 3.3% in 2025 (BLS). The OEWS survey leaves out owners of unincorporated practices who pay themselves from profits, which is one reason its count is lower.

The group is far wider than allergy. All-other physicians made up 45.4% of the 754,760 U.S. wage and salary jobs in BLS’s broad Physicians group (SOC 29-1210, which does not include surgeons) in May 2025 (BLS) (our calculation).

How much do physicians in the all-other group earn?

The median annual wage for U.S. wage and salary jobs in Physicians, All Other was $265,930 in May 2025, per BLS OEWS (BLS). That was 5.2 times the $50,980 median for all U.S. occupations (BLS) (our calculation). These figures describe the whole all-other group, not allergists, and they cover wages and salaries only, not practice owners’ profits.

Pay in the group is spread wide. One in ten of these jobs paid less than $69,170 a year in May 2025 (BLS), and one in ten paid more than $452,360 (BLS). OEWS does not break the group down by role or specialty, so these numbers cannot show what an allergist earns.

Where do physicians in the all-other group work?

Offices of physicians (NAICS 6211) employed 150,920 U.S. wage and salary workers in Physicians, All Other in May 2025, per BLS OEWS (BLS): 44.0% of the group (our calculation). General medical and surgical hospitals (NAICS 6221) employed 107,730 (BLS), or 31.4% (our calculation).

In May 2025 the median annual wage for the group was $311,390 in physician offices (BLS) and $122,260 in those hospitals (BLS), so the office median was 2.5 times the hospital median (our calculation). OEWS does not say which roles sit behind that gap. BLS has no separate industry for allergy practices: they are counted inside offices of physicians, the shared industry in the next section.

How many all-other physicians work in Florida, the Miami area and the Port St. Lucie area?

BLS OEWS estimated 23,390 wage and salary jobs in Physicians, All Other in Florida in May 2025 (BLS), 6.8% of the U.S. count (our calculation). Florida’s median annual wage for the group was $262,180 (BLS), 1.4% below the U.S. median (our calculation).

BLS publishes no OEWS estimates for counties, so Palm Beach and Broward counties appear inside the Miami-Fort Lauderdale-West Palm Beach metro area, and Martin County inside the Port St. Lucie metro area. Every figure in this table is all-other physicians, not allergists.

The Miami metro area held 33.7% of Florida’s jobs in the group (our calculation). A location quotient above 1 means the occupation’s share of local jobs is larger than its share of all U.S. jobs, so the group is more concentrated in the Miami metro area, at 1.27, and less concentrated in the Port St. Lucie metro area, at 0.71. BLS printed job counts and dollar wages for both metro areas, with no suppression or top-code footnote on this occupation. The Port St. Lucie count is small, so treat it with more care than the state total: its relative standard error is 13.8%.

How fast are all-other physician jobs expected to grow?

BLS projects jobs in Physicians, All Other to grow 3.4% from 2025 to 2035, per its Employment Projections (BLS), about the same as the 3.5% projected for all occupations over that decade (BLS). The Occupational Outlook Handbook puts that at 380,100 U.S. jobs in 2035, up from 367,400 in 2025 (BLS). BLS expects about 9.4 thousand openings a year in the group from 2025 to 2035, from growth and from replacing workers who leave the occupation (BLS). These projections cover the whole all-other group. BLS publishes no projection for allergists.

How many physician offices of all specialties are there in the U.S.?

Allergy practices are counted inside offices of physicians (NAICS 621111), an industry shared with every physician specialty except mental health specialists, so every figure in this section covers all physician offices, not allergy practices alone. Other specialty pages, such as our ophthalmology video statistics and dermatology video statistics, carry the same shared figures.

BLS’s Quarterly Census of Employment and Wages (QCEW), which counts employers covered by unemployment insurance, averaged 226,698 private physician offices of all specialties in the U.S. in 2025 (BLS), up from 204,988 in 2019 (BLS): a rise of 10.6% (our calculation). Those offices averaged 2.9 million jobs (2,904,306) in 2025 (BLS), counting all staff and not only physicians, and average annual pay was $116,597 (BLS).

The Census Bureau’s County Business Patterns counted 204,617 U.S. employer physician offices of all specialties in 2023, the newest year available when we checked (Census). Census’s Nonemployer Statistics counted 190,427 U.S. physician-office businesses with no paid staff in 2024 (Census). Those two counts cover different years and different kinds of business, so we do not add them. A nonemployer is any business with no paid employees, which can include part-time or side income, so that count is not a count of full-time practices.

How many physician-office businesses of all specialties had no paid staff in 2023?

Nonemployer businesses made up 47.7% of U.S. physician-office businesses of all specialties in 2023 (our calculation). That share sets Census’s 2023 Nonemployer Statistics beside its 2023 County Business Patterns, so both inputs come from one year. A nonemployer can be side or consulting income, so this is a share of businesses on paper, not of full-time practices. The table covers all physician offices, not allergy practices.

How many physician offices of all specialties are there in Florida and in Palm Beach, Broward and Martin counties?

Florida averaged 21,918 private physician offices of all specialties (NAICS 621111) in 2025, per BLS’s QCEW (BLS): 9.7% of the 2025 U.S. total (our calculation). Census’s newest Nonemployer Statistics, for 2024, counted 19,222 Florida physician-office businesses with no paid staff (Census).

Together Palm Beach, Broward and Martin counties averaged 4,556 private physician offices of all specialties in 2025, 20.8% of Florida’s total (our calculation from QCEW annual averages). The two columns come from different years and different kinds of business, so we do not add them. Neither BLS nor Census publishes a county count of allergy practices.

How much physician-office revenue comes from respiratory diagnoses?

U.S. employer offices of physicians of all specialties (NAICS 621111) had receipts of $630,209,309 thousand (about $630 billion) in 2022, per the 2022 Economic Census, the Census Bureau’s full count of businesses every five years (Census). Census splits those receipts by the ICD-10 chapter of the patient’s primary diagnosis. Diseases of the respiratory system (J00-J99) brought in $30,588,660 thousand (about $30.6 billion) in 2022 (Census), or 4.9% of the industry’s receipts (Census).

That chapter holds asthma and allergic rhinitis along with pneumonia and every other respiratory disease, so the line takes in far more than allergy care. No line in the Economic Census names allergy. The line also leaves out hospitals and the other industries Census counts separately.

Who pays physician offices of all specialties?

Census publishes revenue by payer only for all U.S. physician offices (NAICS 6211, which also includes psychiatrists’ offices). These are two of the payer lines in the 2022 Economic Census:

The 2022 Economic Census does not split any payer’s spending by specialty, so these shares describe all U.S. physician offices, not allergy practices.

How many physician offices of all specialties earn money from telemedicine?

86,466 U.S. employer offices of physicians of all specialties (NAICS 621111) reported some revenue from telemedicine services in 2022, per the 2022 Economic Census (Census): 42.9% of such offices (our calculation). The 2022 table counts offices with any telemedicine revenue. It does not say how much of their revenue came from it, and it does not break out allergy.

How much do physician offices of all specialties spend on advertising?

U.S. offices of physicians of all specialties (NAICS 6211) spent $1,815,721 thousand, about $1.8 billion, on advertising and promotion in 2024, per the Census Bureau’s Annual Integrated Economic Survey (Census). That was 0.28% of their total 2024 operating expenses (our calculation).

The same survey put advertising at $2,129,047 thousand, about $2.1 billion, in 2023 (Census), or 0.36% of that year’s operating expenses (our calculation). The 2024 figure was 14.7% lower (our calculation). Both are sample estimates, so part of that gap may be sampling error. Census does not publish advertising spending for allergy practices or for NAICS 621111 on its own.

How concentrated are physician offices of all specialties?

The four largest firms took 6.2% of the 2022 receipts of U.S. offices of physicians of all specialties (NAICS 621111), per the 2022 Economic Census (Census). The fifty largest took 23.2% (Census). Census publishes no concentration figure for allergy practices, so these shares describe physician offices as a whole.

How many Americans have a diagnosed allergy?

Close to a third of Americans have one. In 2024, 31.7% of U.S. adults and 29.5% of children ages 0-17 had a diagnosed seasonal allergy, eczema or food allergy, according to the National Health Interview Survey (NHIS) run by CDC’s National Center for Health Statistics (NCHS adults) (NCHS children). NHIS is a household interview. An adult counted only after answering yes to having the condition and yes to having ever been told so by a doctor or other health professional; an adult answered the same two questions for each sample child. Nobody in the survey was tested.

The earlier round of the same survey allows a comparison. The share of adults with any of the three was 31.8% in 2021 and 31.7% in 2024 (NCHS, 2021 adults); for children it was 27.2% and 29.5% (NCHS, 2021 children). Diagnosed food allergy among adults was 6.2% in 2021 and 6.7% in 2024 (NCHS, 2021 adults); among children it was 5.8% and 5.3% (NCHS, 2021 children). The 2024 briefs report no test of these changes. Among children, parent-reported food allergy in 2024 was 3.9% at ages 0-5 (NCHS) and 6.9% at ages 12-17 (NCHS).

Why do food allergy numbers disagree?

They measure different things. In 2024, NHIS put diagnosed food allergy at 6.7% of adults; a 2015-2016 survey of 40,443 U.S. adults led by Gupta in JAMA Network Open 2019 put convincing food allergy at 10.8%, a gap of 4.1 percentage points (our calculation), and found 19.0% of adults said they had a food allergy (Gupta 2019). For children, NHIS found 5.3% in 2024, while the same research group’s 2015-2016 survey of parents of 38,408 children (Pediatrics 2018) estimated 7.6% after removing reactions that did not fit IgE-mediated allergy, a gap of 2.3 points (our calculation) (Gupta 2018). More than 11% of children were perceived as food-allergic by a parent in that survey (Gupta 2018).

NIAID, the NIH institute that leads food allergy research, states that food allergy affects approximately 8 percent of children and nearly 11 percent of adults (NIAID). Those figures are close to the Gupta surveys rather than the NHIS diagnoses. The survey respondents who reported a convincing allergy were not clinically tested. Among food-allergic adults in the 2015-2016 survey, 48.0% developed a food allergy as an adult (Gupta 2019). Among food-allergic children, 42.3% had at least one severe reaction reported by a parent (Gupta 2018), 40.7% had a current epinephrine autoinjector prescription (Gupta 2018), and 19.0% had a food-allergy emergency department visit in the previous year (Gupta 2018).

Two advocacy groups publish totals that differ for the same reason. Food Allergy Research & Education (FARE) states that 33 million people in the United States have at least one food allergy (FARE); its footnotes point to the Gupta surveys and Census population counts. The Asthma and Allergy Foundation of America (AAFA), whose references list the NHIS briefs, states that nearly 22 million people have food allergies as of 2024 (AAFA) and that more than 106 million people have allergies of any of the three types (AAFA). FARE also states that 3.4 million U.S. patients have a food-allergy emergency room visit each year (FARE). The footnotes attached to that figure are the same surveys and Census counts, so it is scaled from survey answers rather than counted from hospital records.

How many people test positive for an allergen?

A positive blood or skin test measures sensitization, not diagnosed allergy. In NHANES 2005-2006, 44.6% of Americans aged 6 and over had detectable serum IgE to at least one of 19 inhalant or food allergens (Salo et al., J Allergy Clin Immunol 2014) (Salo 2014). In the earlier NHANES III (1988-1994), 54.3% of the population tested positive to at least one of 10 allergens by skin-prick test (Arbes et al., 2005) (Arbes 2005). The two studies used different tests and different allergen panels, so the gap between them is not a measured trend.

Are food allergies rising or falling?

The long NHIS series rose. Its older question asked whether a child had “any kind of food or digestive allergy” in the past 12 months, and the answer was yes for 3.4% of U.S. children in 1997-1999 and 5.1% in 2009-2011 (NCHS). NCHS warns that estimates from before the 2019 questionnaire redesign are not directly comparable with later years (NCHS). One recent records study points down in the youngest children. In an observational 2025 Pediatrics study of the AAP’s primary-care network, the cumulative incidence of diagnosed IgE-mediated food allergy among children 0-3 was 1.46% for children entering the cohort before the early-introduction guidelines (September 2012-August 2014) and 0.93% for those entering after the 2017 addendum (February 2017-January 2019) (Gabryszewski 2025). The study counted diagnoses in primary-care records rather than testing every child.

How common is asthma in the United States?

CDC counted 27,807,000 Americans with current asthma in 2023, using self-reported and parent-reported answers in NHIS: 23,004,000 adults, or 8.9% of adults, and 4,804,000 children under 18, or 6.7% of children (CDC). Among people with current asthma, 42.3% had one or more asthma attacks in the past 12 months (CDC).

The annual NHIS table shows no sharp change since 2019: 8% of adults in 2019 (NCHS) and 8.5% in 2025 (NCHS), and 7% of children in 2019 (NCHS) and 6.3% in 2025 (NCHS).

Hospital and death records, rather than survey answers, supply the severe-event counts. CDC reports 1,009,419 emergency department visits with asthma as the primary diagnosis in 2023 (CDC, from HCUP NEDS), 131,985 inpatient stays with asthma as the primary diagnosis (CDC, from HCUP NIS), and 3,624 deaths with asthma as the underlying cause (CDC WONDER). The crude death rate was 22.6 per million among Black non-Hispanic Americans (CDC WONDER) and 10.4 per million among White non-Hispanic Americans (CDC WONDER).

How common is asthma in Florida and in Palm Beach, Broward and Martin counties?

In 2023, 8.5% of Florida adults, or 1,559,429 people, had current asthma, according to CDC’s tabulation of the Behavioral Risk Factor Surveillance System, a telephone survey that is not NHIS (CDC, BRFSS 2023). CDC’s child table, built on the 2023 National Survey of Children’s Health, a parent-completed survey, estimates 305,950 Florida children under 18 with current asthma (CDC, NSCH 2023).

CDC’s PLACES models adult asthma for every county from BRFSS answers; the county figures are estimates, not counts taken in the county. The 2025 release puts current asthma among adults in 2023 at 9.2% in each of the three South Florida counties, and the range across Florida’s 67 counties runs from 8.5% in Miami-Dade County (CDC PLACES) to 11.1% in Gadsden County (CDC PLACES). Applying each county’s rate to its PLACES adult population gives about 270,900 adults with current asthma across the three counties (our calculation).

How often does anaphylaxis happen?

Our searches of PubMed and the web did not turn up an annual federal count of anaphylaxis, so these figures come from surveys and one-off analyses of claims and hospital data. A telephone survey of 1,000 U.S. adults, published in 2014, found 1.6% had a history meeting criteria for very likely anaphylaxis and 5.1% met the looser criteria for probable anaphylaxis (Wood et al., J Allergy Clin Immunol 2014; the abstract lists two authors at AAFA) (Wood 2014). Those are lifetime, self-reported estimates.

Emergency visits rose in the insurance-claims and hospital data that have been studied. In a national claims database of commercially insured and Medicare Advantage patients, the rate of emergency visits for anaphylaxis rose 101% from 2005 to 2014 (Motosue 2017). In a claims analysis of children under 18, emergency visits for food-induced anaphylaxis rose 214% over the same years (Motosue 2018). In a nationally representative emergency database, visits among infants and toddlers reached 32 per 100,000 in 2015, and the share of those visits ending in a hospital admission fell to 6% (Robinson 2021). Claims data leave out the uninsured and Medicaid.

Hospital admissions rose more slowly. In the Nationwide Inpatient Sample the rate of anaphylaxis-related hospitalizations was 21.0 per million population in 1999 and 25.1 in 2009 (Ma 2014), and a separate National Inpatient Sample study found overall anaphylaxis hospitalizations stable from 2001 to 2014, with food-related admissions among ages 5 to 14 rising 5.86% per year (Shrestha 2019).

Deaths are rare in the data. Multiple Cause of Death records for 1999-2009 count 186-225 anaphylaxis deaths per year, and the average case fatality rate among emergency department or hospital presentations from 2006 to 2009 was 0.3% (Ma 2014). Of the anaphylaxis deaths on U.S. death certificates in 1999-2010, 58.8% were attributed to medications (Jerschow 2014). After an emergency visit for anaphylaxis, claims data for 18,279 patients show 46% filled an epinephrine auto-injector prescription and 29% had allergy or immunology follow-up within a year (Motosue 2017).

Do allergy drug and test makers tell investors about video?

Only 3 of the newest annual reports from 9 named allergy drug and test makers use the word “video,” and 0 describe making video for allergists or patients (our calculation from the filings on SEC EDGAR; fiscal 2025 reports, except Aimmune’s, which is fiscal 2019). DBV and Sanofi use the word for board meetings by videoconference, and Regeneron for how it communicates with video and writing to its own employees (Regeneron 10-K). Annual reports describe channels in broad terms, so a missing word does not mean a company makes no videos.

ARS Pharmaceuticals shows the gap. Its fiscal 2025 10-K never uses the word, yet it says it markets neffy, an epinephrine nasal spray, across streaming platforms, broadcast and cable television, and digital channels including Facebook, Instagram and waiting room TVs in doctors’ offices (ARS 10-K). Its branded consumer advertising began in May 2025, and linear television followed in June 2025 (ARS 10-K). It began advertising its getneffy.com virtual prescriber site in November 2025 (ARS 10-K). The 10-K gives no advertising dollars and no ad counts.

4 of the 9 reports use the word “allergist” at all: ARS, DBV, Aimmune and Sanofi (our calculation). 0 name YouTube or TikTok, and only ARS names Instagram and Facebook (our calculation).

How do allergy drug makers reach allergists?

ARS Pharmaceuticals reported the largest of the four field forces these filings state: 106 people in its fiscal 2025 10-K, counting reps, area managers and national directors (ARS 10-K). It says it targets about 20,000 high-volume prescribers, particularly allergists and pediatricians, who write 50 to 55% of US epinephrine prescriptions (ARS 10-K), which works out at 189 per person (our calculation). A partner, ALK’s US unit, adds about 70 reps who call on pediatricians, and ARS has 10 virtual reps (ARS 10-K).

The ratios use each seller’s own numbers and describe a plan or a call list, not how often a rep sees a doctor.

Allergists also appear as a channel. ARS says about 3,400 healthcare professionals had enrolled in its neffy experience program by February 2026 (ARS 10-K), which gives allergists doses of the spray for in-office use during oral food challenges or allergen immunotherapy (ARS 10-K). It also funds continuing medical education with allergist societies, speaker bureaus and peer-to-peer programs (ARS 10-K). Sanofi says its roughly $9.5 billion purchase of Blueprint gave it an established presence among allergists, dermatologists and immunologists (Sanofi fiscal 2025 20-F).

How many US allergists do the filings say there are?

The filings disagree by up to 2,000 allergists (our calculation). QHSLab’s fiscal 2025 10-K says fewer than 3,000 practicing board-certified allergists, plus about 2,400 otolaryngologists who specialize in allergy (QHSLab 10-K). DBV Technologies’ fiscal 2025 10-K says about 4,500 (DBV 10-K). Aimmune’s fiscal 2019 10-K said about 5,000 practicing allergists (Aimmune 10-K). None of the three names a source, and the definitions differ. Each has a reason to pick its number: QHSLab sells allergy tests and immunotherapy to primary care doctors, so a shortage of allergists supports its pitch, while DBV and Aimmune size a sales force against the count. See this page’s practice section for board certification counts.

QHSLab’s fiscal 2024 10-K said there was about one specialist for every 11,000 allergy sufferers (QHSLab 10-K), and that full-time allergists and immunologists would decline about 7 percent while demand rose 35 percent (QHSLab 10-K). It named no source for the projection, and its fiscal 2025 10-K dropped both figures while keeping the head count.

What do epinephrine sellers report?

Viatris reported EpiPen Auto-Injectors net sales of $469.7 million worldwide in fiscal 2025 (Viatris 10-K), up 19.8% from fiscal 2024 (our calculation). That is 47.0% of the approximately $1 billion Mylan reported for 2015 and 2016 (our calculation). Viatris’s report gives one line and does not separate branded EpiPen from its authorized generic.

The fall came with competition. Mylan said EpiPen first reached $1 billion in annual net sales in 2014 (Mylan 10-K), launched the first authorized generic on December 16, 2016 (Mylan 10-K), and reported that EpiPen sales fell about $655.4 million in 2017, citing that generic, higher government rebates and more competition (Mylan 10-K). Teva says it launched its generic in 2018 (Teva 10-K). Mylan’s fiscal 2011 10-K claimed more than 95% of the US auto-injector market and more than 90% worldwide (Mylan 10-K); the fiscal 2012 to 2019 reports we checked drop the percentage, and Viatris gives none. Aquestive, which wants to compete with its own product, says a generic auto-injector is now the leading self-administered form of epinephrine, with no share figure (Aquestive fiscal 2025 10-K).

neffy is the newcomer. ARS reported $72.2 million in US net product revenue for fiscal 2025 (ARS 10-K), which is 15.4% of EpiPen’s worldwide sales that year (our calculation; US against worldwide, so only a scale comparison). Its selling, general and administrative expenses were $230.1 million (ARS 10-K), 3.2 times that revenue (our calculation); the figure includes non-sales costs, so it does not measure advertising return. ARS estimates that branded EpiPen marketing lifted sales by 31% over organic growth before generics arrived, a figure it publishes in support of its own advertising and gives without method (ARS 10-K).

The FDA has written to ARS about those ads. ARS says it received FDA untitled letters on September 9, 2025 and January 23, 2026, raising concerns that its television ads made false or misleading claims (ARS 10-K). Regeneron’s fiscal 2025 10-K says the federal government has announced an initiative on prescription drug advertising that is expected to expand oversight of social media promotional activities (Regeneron 10-K). Aquestive’s rival epinephrine film is not on the market: it received an FDA Complete Response Letter dated January 30, 2026 (Aquestive 10-K).

How do sellers size the allergy market?

ARS Pharmaceuticals, in its fiscal 2025 10-K, puts the people in the US who experience Type I allergic reactions at about 40 million (ARS 10-K) and builds three dollar estimates on top. Each is a seller’s number: it assumes neffy’s own price and net yield, and ARS benefits from a large figure.

neffy’s fiscal 2025 revenue equals 4.0% of the first of those estimates (our calculation), which is not an independent market share. Aimmune said in its fiscal 2019 10-K that the US market for approved peanut allergy treatments could exceed one billion dollars a year (Aimmune 10-K).

DBV, which is seeking approval for a peanut patch, estimates about 670,000 US children ages 1 to 7 have peanut allergy (DBV fiscal 2025 10-K). It says market research, which it does not name, suggests nearly 60% of peanut-allergic children are cared for by allergists (DBV fiscal 2025 10-K), and that if approved it plans digital and social-media campaigns to prompt parents to raise the patch with their child’s allergist (DBV fiscal 2025 10-K). Evommune, developing a rival treatment, says concerns about Xolair have limited its use predominantly to allergists, at approximately 10% penetration in antihistamine-refractory chronic spontaneous urticaria (Evommune fiscal 2025 10-K).

Aimmune also flagged a practical limit: it said there was no dedicated reimbursement code for administering oral immunotherapy (Aimmune fiscal 2019 10-K). That was its position in early 2020, and coding may have changed since.

What do the largest asthma and allergy drug and test makers report?

Sanofi reported Dupixent net sales of €15,714 million in fiscal 2025, 36.0% of its net sales (Sanofi 20-F), including €11,538 million in the US (Sanofi 20-F), or 73.4% (our calculation). Regeneron, which shares the profits, reports Dupixent and Kevzara together at $18,381.3 million (Regeneron 10-K). Sanofi’s figure covers every indication and is not split: it says Dupixent was approved for asthma by the FDA in October 2018 (Sanofi 20-F), so allergy and asthma revenue alone cannot be read from either filing.

Novartis reports Xolair net sales of $1,723 million in fiscal 2025 for all indications (Novartis 20-F), up 17.8% from fiscal 2023 (our calculation). That excludes the US, where Genentech records the sales and Novartis co-promotes. Thermo Fisher’s fiscal 2025 10-K describes blood-test systems for allergy, asthma and autoimmune diseases without naming a product (Thermo Fisher 10-K); its 10-K for fiscal 2021 is the last that names ImmunoCAP (Thermo Fisher 10-K). It gives no sales figure for allergy tests.

Two major allergy immunotherapy makers cannot be checked this way. ALK-Abelló’s only EDGAR record is a Form F-6 registration for American depositary receipts, and full-text search finds no annual report filed by Stallergenes Greer, so there is none to read for either company.

How often do annual reports mention allergists?

8 Form 10-K annual reports filed in 2025 contained “allergist” or “allergists,” against 4 in 2001 and a peak of 14 in 2005, by our count with SEC EDGAR full-text search (our calculation). From 2001 to 2025, 154 such filings came from 49 registrants, and 7 more were filed in 2026 through November 8 (our calculation). The yearly counts, filer names and query URLs are in our EDGAR counts file.

Full-text search has limits worth stating. It covers filings from 2001 on. It counts Form 10-Ks only, so Sanofi and Novartis, which file Form 20-F, are outside it, as are private companies such as Kaleo and every private allergy practice. It leaves out 10-K/A amendments and the older 10-K405 form, it does no stemming, and it misses other wording such as “allergy specialist.” Filing year 2025 mostly means fiscal 2024 reports. The count measures a word, not a business.

We read all 8 of the filings from 2025. 6 come from companies that sell to allergists or plan to, one sizes its market by the shortage of allergists, and one only cites a paper with the word in its title (our calculation; see the contexts file). Vision Sciences, an endoscope maker, accounts for 12 of the 154 filings, more than any other registrant (our calculation). Its mentions note that allergists perform laryngoscopies.

19 of the 154 also contain “video,” and video almost never means marketing there. In 14 it is a device feature such as a video endoscope, and in 4 it is contract, meeting or compliance text (our calculation). 1 uses it for remote care: LifeMD, whose Cleared telehealth brand offered care from US-licensed allergists and nurses (LifeMD fiscal 2022 10-K), lists patient-provider audio/video interfacing on its platform (LifeMD fiscal 2022 10-K). 0 of the 19 describe a marketing, educational or training video (our calculation; we read each and also ran a phrase search for those words beside “video”).

LifeMD is also the only filer to pair allergists with YouTube: 3 of its 10-Ks, filed in 2022, 2023 and 2024 (our calculation), list YouTube among whole-company marketing channels (LifeMD 10-K). Filings pairing an allergist word with “epinephrine” numbered 27 from 2001 to 2025, and with “immunotherapy,” 34 (our calculation).

How does FDA regulate allergy shots and allergen extracts?

FDA’s list of standardized injectable allergen extracts counts 19 products, each compared with a U.S. reference standard for potency: cat hair and cat pelt, dust mites, grasses, short ragweed and insect venoms (FDA). FDA’s list page is several years old, so the count may have changed. Extracts with no U.S. reference standard are called non-standardized, and FDA’s rule lets their manufacturers keep using “unstandardized potency designations” until FDA tells them a potency test exists that measures allergenic activity (eCFR, 21 CFR 680.3). FDA says injectable extracts for food allergies are used “only for diagnostic purposes” (FDA). It says sublingual allergen extract tablets are “used for treatment only”, for allergic rhinitis with or without allergic conjunctivitis (FDA).

How many major food allergens does U.S. law recognize?

U.S. labeling law names the eight major foods or food groups listed in the Food Allergen Labeling and Consumer Protection Act (Public Law 108-282), plus sesame, which applies to food entering interstate commerce on or after January 1, 2023 (Public Law 117-11). That Act was approved on August 2, 2004 (Public Law 108-282), and its labeling amendments apply to any food labeled on or after January 1, 2006 (Public Law 108-282). The FASTER Act added sesame (Public Law 117-11).

Congress’s 2004 findings in the labeling Act say those foods account for 90 percent of food allergies (Public Law 108-282). The same findings estimate that roughly 30,000 people a year need emergency room treatment for allergic reactions to food (Public Law 108-282) and that 150 individuals die from them (Public Law 108-282). These are estimates Congress adopted when it passed the Act. The Act names no study, and they are not current counts.

Which FDA approvals define food allergy and anaphylaxis treatment?

FDA’s licensing letter for Palforzia, an oral immunotherapy for peanut allergy, is dated January 31, 2020 (FDA approval letter). FDA’s product page now allows treatment to start in patients aged 1 through 17 years with a confirmed peanut allergy, alongside a peanut-avoidant diet (FDA). The supplement that extended the age range to younger children carries an approval letter dated July 26, 2024 (FDA). Palforzia is restricted: its approval requires a drug safety program under which pharmacies, practitioners or health care settings that dispense it are “specially certified” (FDA approval letter).

FDA approved Xolair (omalizumab) for IgE-mediated food allergy on February 16, 2024 (FDA), for certain adults and children 1 year or older (FDA). FDA says patients on Xolair “must continue to avoid foods they are allergic to” and that it is not approved for the immediate emergency treatment of allergic reactions (FDA). FDA approved neffy, an epinephrine nasal spray, on August 09, 2024, for adults and children who weigh at least 30 kilograms (about 66 pounds) (FDA). An FDA official called it the first epinephrine product for anaphylaxis that is not given by injection (FDA).

What do FDA’s drug advertising rules require of a broadcast drug ad?

Under 21 CFR 202.1, a prescription drug ad broadcast on radio or television must carry the major side effects and contraindications in the “audio or audio and visual parts” of the presentation (eCFR, 21 CFR 202.1). A final rule effective May 20, 2024 (Federal Register) requires that major statement to run in audio and text at the same time in TV-format ads, which the rule calls “dual modality” (eCFR, 21 CFR 202.1). The rule’s misbranding paragraph refers to an ad issued or caused to be issued by the “manufacturer, packer, or distributor” of the drug (eCFR, 21 CFR 202.1). HHS’s penalty table sets the maximum civil penalty for a false or misleading direct-to-consumer drug ad at $377,701 for a first violation in any 3-year period (eCFR, 45 CFR 102.3).

What has FDA told makers of epinephrine and asthma drugs about their ads?

FDA’s Office of Prescription Drug Promotion sent kaleo an untitled letter on Auvi-Q, an epinephrine auto-injector, dated July 17, 2024 (FDA close-out letter). The letter concerned a video post on an individual’s personal Instagram account, made in a disclosed paid “partnership with auvi-q” (FDA). FDA wrote that the post presents the drug’s benefits but “fails to include any risk information” (FDA). The post sent viewers to an Important Safety Information account, and FDA said that “does not mitigate the misleading impression” left by omitting the risks (FDA). FDA later closed out the letter (FDA close-out letter).

FDA sent ARS Pharmaceutical Operations an untitled letter on a neffy TV ad dated September 9, 2025 (FDA). FDA said the ad’s “No needles! Goodbye!” claims suggest patients can “completely avoid using any injectable treatments” for allergic emergencies, which has not been demonstrated (FDA). A second letter, dated January 23, 2026 (FDA close-out letter), covered a TV ad with similar claims. It also said the ad showed the device “out of its blister packaging”, while the labeling says to store it in the blister pack until ready to use (FDA). FDA later closed out that letter too (FDA close-out letter). In a separate letter on a TV ad for the asthma biologic Fasenra, FDA said the ad’s “before-and-after presentations” implied an improvement in social and emotional functioning (FDA).

On the same day as the first neffy letter, FDA announced it was sending “thousands of letters” to drug companies (FDA) and issuing approximately 100 cease-and-desist letters over misleading ads (FDA). It also said it was starting rulemaking to close an “adequate provision” loophole it dates to 1997 (FDA). We found no proposed rule on that point in the Federal Register when we checked for this edition. These letters went to drug makers, not physician practices. An untitled letter is a regulator’s notice to one company, not a court finding.

What does Florida law say about epinephrine in schools and public places?

Florida’s school statute lets a student at risk for life-threatening allergic reactions carry and self-administer an FDA-approved epinephrine delivery device at school, at school activities and in transit, if the school has “parental and physician authorization” (Florida Statutes 1002.20). A public school “may purchase a supply” of those devices from a wholesale distributor for use in an anaphylactic reaction (Florida Statutes 1002.20). Each school that serves students in kindergarten through grade 8 must provide training in preventing and responding to allergic reactions, including anaphylaxis (Florida Statutes 1002.20). The same statute set a deadline of October 1, 2025 for State Board of Education rules that identify an approved training curriculum (Florida Statutes 1002.20).

Outside schools, Florida’s Emergency Allergy Treatment Act lets authorized entities stock epinephrine auto-injectors (Florida Statutes 381.885). Its definition of authorized entity includes “restaurants, recreation camps, youth sports leagues, theme parks and resorts, and sports arenas” (Florida Statutes 381.88). A person who completes an approved training program may obtain a certificate for a $25 application fee (Florida Statutes 381.88). An entity may also make stocked auto-injectors available to uncertified people if they are kept in a “locked, secure container” and released only on remote authorization by a health care practitioner. The statute says a consultation by audio or televideo for this purpose is not considered the practice of telemedicine (Florida Statutes 381.885).

What do Florida’s advertising and telehealth rules say?

Florida’s physician statute lists “False, deceptive, or misleading advertising” as grounds for discipline (Florida Statutes 458.331), and the Board of Medicine may fine up to $10,000 for each count (Florida Statutes 456.072). Any ad naming a practitioner must identify the type of license that person holds (Florida Statutes 456.072). The Board’s advertising rule treats an ad as false, deceptive or misleading if it creates false or “unjustified expectations of beneficial assistance” (Florida Administrative Code 64B8-11.001). A physician who advertises on electronic media must keep an exact copy of each audio or video ad for at least six months after it airs (Florida Administrative Code 64B8-11.001). Florida’s telehealth statute covers “synchronous or asynchronous” technology, so both live video visits and store-and-forward review count (Florida Statutes 456.47).

What do FTC rules say about patient testimonials and reviews in allergy practice ads?

The FTC’s Endorsement Guides, in the text published on July 26, 2023 (eCFR, 16 CFR Part 255), read a patient testimonial as a claim that the result is typical. If the advertiser cannot back that up, the ad should disclose the generally expected performance (eCFR, 16 CFR 255.2). When an endorsement uses both pictures and sound, as a video does, the disclosure belongs in both the visual and audible portions (eCFR, 16 CFR 255.0). The FTC’s rule on consumer reviews and testimonials (16 CFR Part 465) took effect on October 21, 2024 (Federal Register). The maximum civil penalty for knowingly violating an FTC rule is now $53,088 per violation (eCFR, 16 CFR 1.98).

When does a patient video from an allergy practice need HIPAA authorization?

HIPAA defines marketing as a communication about a product or service that encourages people to “purchase or use the product or service” (eCFR, 45 CFR 164.501). To use protected health information for marketing, a covered entity such as an allergy practice “must obtain an authorization” from the patient, with exceptions only for face-to-face communications and promotional gifts of nominal value (eCFR, 45 CFR 164.508). HIPAA’s de-identification rule lists “Full face photographic images” and comparable images among patient identifiers (eCFR, 45 CFR 164.514). HHS’s Office for Civil Rights has enforced this against a practice’s marketing. Complete P.T., Pool & Land Physical Therapy, a Los Angeles-area practice and not an allergy practice, agreed in 2016 to pay $25,000 after posting patient testimonials with full names and full-face photos on its website without valid authorizations (HHS OCR).

What is Medicare’s current telehealth status?

CMS’s Telehealth FAQ says Medicare patients can receive telehealth anywhere in the United States, at home included, through December 31, 2027 (CMS). After that, outside behavioral health, patients will generally need to be in a medical facility in a rural area (CMS). CMS publishes its list of covered telehealth codes separately, and we did not check it for this edition, so we make no claim here about whether a given allergy test or immunotherapy service is on it. This section summarizes published rules and letters. It is not legal or medical advice.

What do the popular allergy numbers really say?

In the 2024 National Health Interview Survey, 31.7% of U.S. adults (CDC NCHS, archived) and 29.5% of children (CDC NCHS, archived) had a diagnosed seasonal allergy, eczema or food allergy. The numbers allergy practices, associations and video vendors repeat are mostly older, narrower, or added together from separate surveys. We traced six of them to the study, agency or vendor that produced them and read what each one measured. Pages that repeat a number are linked only as dated evidence of how it spread, never as a source for the number itself.

“More than 50 million Americans have allergies”

The number began as a skin test estimate, not a count of people with allergies. A National Institute of Allergy and Infectious Diseases (NIAID) fact sheet captured in February 1997 said there were no solid statistics and that allergies might affect as many as 40 to 50 million people (NIAID, archived), the earliest form we found. Its footnote is a 1987 paper by Gergen and colleagues in the Journal of Allergy and Clinical Immunology. The federal NHANES II survey tested a sample of 16,204 people aged 6 to 74 (Journal of Allergy and Clinical Immunology) between 1976 and 1980, and 20.2% reacted to at least one of eight allergens (Journal of Allergy and Clinical Immunology). A positive skin test shows sensitization. It does not show symptoms or a diagnosis.

The wording then grew. NIAID’s January 2000 edition dropped the caveat and said more than 50 million (NIAID, archived). Its January 2002 edition said more than 50 million Americans suffer from allergic diseases each year and cited a report by the American Academy of Allergy, Asthma & Immunology in place of the survey (NIAID, archived); we could not read that report. The Asthma and Allergy Foundation of America (AAFA), a patient advocacy group, wrote an estimated 50 million in 2005 (AAFA, archived). “More than 50 million Americans suffer from allergies each year,” said a CDC page of tips for TV writers, last reviewed in February 2011, with no citation for the figure (CDC, archived). The American College of Allergy, Asthma and Immunology (ACAAI), an association of allergists, still titled its facts page “50 Million Americans Have Allergies” when we read it in November 2026 (ACAAI), though the text on that page now gives a larger number.

Later skin test and survey figures do not match it. NHANES III, run from 1988 to 1994, found 54.3% of people aged 6 to 59 had a positive test to at least one allergen (Journal of Allergy and Clinical Immunology), and its authors could not say how much of the rise over NHANES II was real. AAFA’s current page says more than 106 million people in the U.S. experience various types of allergies each year, counting seasonal allergy, eczema and food allergy (AAFA). Use instead: “In the 2024 National Health Interview Survey, 31.7% of U.S. adults and 29.5% of children had a diagnosed seasonal allergy, eczema or food allergy.” Do not present more than 50 million as a count of people diagnosed with allergies.

“1 in 13 children has a food allergy”

The line is a rounding of a parent-report survey from 2009 and 2010, and the survey figure has since changed. The earlier federal number was lower: in 2007, CDC’s National Center for Health Statistics (NCHS) reported that 3.9% of children under 18 had a food or digestive allergy in the previous 12 months, by parent report (CDC NCHS, archived). In 2011 Gupta and colleagues, writing in Pediatrics, reported on an online survey of U.S. households from June 2009 to February 2010. For 38,480 children (Pediatrics), an adult in the household answered, and estimated food allergy prevalence was 8.0% (Pediatrics). It was not clinical testing. The Food Allergy Initiative, which funded the study, put it this way in its June 2011 release: now it is 1 in 13 children (Food Allergy Initiative), the earliest wording we found. Gupta said about 1 in every 13 children in the hospital’s release (Children’s Memorial Hospital).

The line survived a new survey. Gupta’s 2018 paper in Pediatrics, from parent-proxy answers for 38,408 children in 2015 and 2016 (Pediatrics), estimated 7.6% (Pediatrics). FARE (Food Allergy Research & Education), an advocacy group that funds research on food allergy, still says one in 13 children (FARE). The federal survey asks a narrower question and finds less: in 2024 the National Health Interview Survey found that 5.3% of U.S. children aged 0 to 17 had a diagnosed food allergy, which NCHS itself words as 1 in 20 (CDC NCHS, archived). Use instead: “In the 2024 National Health Interview Survey, 5.3% of U.S. children had a diagnosed food allergy; a 2015-2016 parent survey led by Gupta estimated 7.6%.” Name the survey every time you use one in 13.

“Video on a landing page lifts conversions by 80%”

The figure is a best case from one video vendor, EyeView, in 2009 and 2010, about financial and tutoring websites, not allergy care. EyeView’s blog reported in December 2008 that eToro visitors who watched its video were 20% more likely to download the product (EyeView, archived). In February 2009 it said UMOO viewers were 80% more likely to become depositing users, comparing viewers with non-viewers for one client (EyeView, archived). Its 2010 white paper said only that “in some cases” the boost was over 80% (EyeView white paper, archived), and the one test it described, the eToro split test, was now almost 32 percent (EyeView white paper, archived).

The scope fell away in repeats. By August 2010 Unbounce, a landing-page software seller, wrote that video on landing pages can increase conversion by 80% (Unbounce, archived). Practice Builders, which sells marketing to healthcare practices, repeated 80 percent and credited Hyperfine Media, naming no study (Practice Builders). In allergy care we found one repeater: a 2026 post by Webtonic, a marketing agency, says video testimonials raise conversion rates by 80% over text-only testimonials, crediting only “healthcare marketing research” (Webtonic). We searched allergy and immunology practice marketing for the figure and found no test by an allergy practice behind it.

The larger later evidence points the other way. Unbounce’s own 2021 analysis of about 35,000 customer landing pages in each of three periods (Unbounce) concluded that video appears to have a minimal or negative impact on landing-page performance regardless of the conversion goal (Unbounce). Use instead: do not cite a conversion lift for allergy practice video; say Unbounce’s 2021 study of 35,000 pages found video had a minimal or negative effect, and judge a practice’s video by its own appointment requests.

“Allergies are the sixth leading cause of chronic illness”

The rank rests on no count we could find, and CDC did print it, on a page for TV writers. The oldest related list we found is a November 1999 brief from the National Academy on an Aging Society. From the 1994 National Health Interview Survey, it named the five most common chronic conditions for all ages: sinusitis, arthritis, orthopedic impairments, hypertension and hay fever (National Academy on an Aging Society, archived). That is a list of how common conditions were, and it counts hay fever alone. AAFA’s 2005 page cited it for allergy as the 5th leading chronic disease (AAFA, archived).

Sixth place appears in NIAID’s January 2002 fact sheet, which said allergies are the 6th leading cause of chronic disease and cited the American Academy of Allergy, Asthma & Immunology’s The Allergy Report (NIAID, archived), the earliest sixth-place wording we found. NIAID’s 1997 and January 2000 editions carry no rank. A fellowship abstract on the American Council of Learned Societies site used sixth leading in 2004 (American Council of Learned Societies). CDC’s page for TV writers, last reviewed in February 2011, said allergies are the 6th leading cause of chronic illness in the U.S., with no source for the rank (CDC, archived). We found no NCHS statistical report that ranks allergies sixth, which is a limited search and not proof that none exists.

Later pages cite one another. ACAAI’s January 2018 page used the CDC sentence word for word, giving 6th, and listed the CDC page among its sources (ACAAI, archived). AAFA’s 2019 page gave 6th with a footnote to ACAAI (AAFA, archived), and Ambetter, a health insurer, still prints the sentence with the 6th rank on a member page (Ambetter). AAFA’s current page has dropped the number and calls allergies one of the most common chronic conditions in the U.S. (AAFA). Use instead: avoid a numbered rank, and say allergies are among the most common chronic conditions in the U.S.

“A food allergy reaction sends someone to the ER every three minutes”

The interval restates a modeled estimate published in 2010 and 2011, and FARE has since replaced it. AAFA’s 2005 page gave 30,000 emergency room visits for food allergy each year (AAFA, archived). In December 2010 Reuters Health reported a new estimate from Clark and colleagues in the Journal of Allergy and Clinical Immunology: about 200,000 emergency room trips a year from 2001 to 2005 (Reuters Health via Fox News). We could not read that letter, which has no abstract in PubMed. The same group’s 2013 paper in Allergy and Asthma Proceedings describes the method: proportions from two multicenter emergency department studies, multiplied against national counts of coded visits. It estimated about 1,892,000 visits over the nine years from 2001 to 2009 (Allergy and Asthma Proceedings).

By January 2012 the Food Allergy & Anaphylaxis Network, whose site foodallergy.org is now FARE’s, wrote that every 3 minutes a food allergy reaction sends someone to the emergency department, about 200,000 visits a year, and that every 6 minutes the reaction is anaphylaxis, citing Clark (FAAN, archived). That is the earliest interval wording we found; a July 2011 capture of the same page has none. A May 2021 proclamation by Michigan’s governor repeated, according to FARE, every three minutes (State of Michigan).

FARE then changed the base. A capture of its statistics page from February 2024 says every 10 seconds (FARE, archived), and the current page gives 3.4 million patients a year, citing the 2018 and 2019 Gupta surveys and a Census Bureau table (FARE). That total rests on survey answers: in the 2018 parent survey, 19.0% of food-allergic children reported an emergency department visit in the previous year (Pediatrics). Estimates built from coded visits run far lower. Clark’s 2013 paper put 2009 at 92,000 visits among children (Allergy and Asthma Proceedings) and 97,000 among adults (Allergy and Asthma Proceedings). Use instead: “Clark and colleagues estimated about 92,000 emergency department visits for food allergy among U.S. children and 97,000 among adults in 2009, using coded visits.” Do not print an interval.

“32 million Americans have food allergies”

The number is a sum FARE published in 2019 from two surveys led by Gupta, and FARE now says 33 million. In February 2019 FARE wrote that new numbers meant 32 million Americans, more than double what it had previously believed (FARE), the earliest wording we found. The sum adds 26 million adults (FARE) to 5.6 million children (FARE). The adult figure comes from Gupta’s 2019 paper in JAMA Network Open, a survey of 40,443 adults by internet and telephone from October 2015 to September 2016, most from a non-probability online panel (JAMA Network Open). It estimated convincing food allergy in 10.8% of adults, a classification of self-reported symptoms and not clinical testing (JAMA Network Open). A May 2021 Michigan proclamation repeated 32 million with credit to FARE (State of Michigan).

FARE’s August 2023 statement raised the figure by applying a 2020 review’s “over 10%” of the U.S. population to a census total (FARE), and said the number with at least one IgE-mediated food allergy exceeds 33 million (FARE). The federal survey again asks a narrower question: in 2024, 6.7% of U.S. adults had a diagnosed food allergy (CDC NCHS, archived). Use instead: “Two Gupta surveys from 2015 and 2016 estimated food allergy in 10.8% of U.S. adults and 7.6% of children by survey report; the 2024 National Health Interview Survey found diagnosed food allergy in 6.7% of adults and 5.3% of children.” Describe 32 million and 33 million as advocacy estimates, not as a count of diagnosed people.

Every popular claim our research pages trace, 853 in all, is on one page: popular video statistics, fact-checked.

How we built this page

We started from the questions people search for about allergist video statistics and looked for the organization that actually produced each answer. Every figure on this page sits in an evidence ledger with its source, the exact table or paragraph it came from, the measurement period, the population measured, and the date we checked it. This edition holds 691 figures from 74 publishers.

On November 8, 2026, each sourced figure on this page was re-fetched with the fetch cache cleared and matched against the recorded wording: CMS’s Medicare Physician & Other Practitioners files through the data.cms.gov data API; BLS occupation wage estimates and the Quarterly Census of Employment and Wages (through the BLS data API and data files) and Employment Projections pages (through Internet Archive copies, because bls.gov refuses automated requests); Census County Business Patterns, Nonemployer Statistics, the 2022 Economic Census and the Annual Integrated Economic Survey (through the Census data API); CDC PLACES through data.cdc.gov; CDC, NCHS and other pages through Internet Archive copies where the live page refuses scripts; NIAID pages; American Board of Allergy and Immunology, American Board of Medical Specialties and ACGME pages, and Florida’s physician workforce reports; eCFR, the Federal Register, FDA pages, public laws on govinfo.gov, the Florida Statutes and the Board of Medicine’s advertising rule; SEC filings on EDGAR; journal abstracts (PubMed abstracts re-read through NCBI’s E-utilities, because the pages answer scripts with a bot check); and the pages behind each popular claim. Our Medicare counts come from CMS’s own files, our YouTube figures from the YouTube Data API and our filing counts from EDGAR full-text search. We left out sources whose robots rules bar AI agents, among them JAMA Network, the Journal of Allergy and Clinical Immunology and its In Practice journal, Annals of Allergy, Asthma & Immunology, WebMD and Healio (for those journals we use only the PubMed abstract), congress.gov (public laws are cited from govinfo.gov) and data.hrsa.gov, and ftc.gov pages (they answer scripts with an error page, so FTC rules are cited from eCFR and the Federal Register). ALK-Abelló and Stallergenes Greer file no annual reports with the SEC, so their figures are not here.

We only cite the producer: government agencies, regulators, company filings and official posts, and the survey owner's own report. We do not cite statistics roundups, Statista-style aggregators, or salary sites without a public method. We did not bypass paywalls or sign-up forms; where a full report was gated, we used only the figures its publisher states publicly.

Figures marked "our calculation" are arithmetic on the cited numbers, and anyone can reproduce them:

This edition contains no Mark Studios customer data.

Limitations

• Allergist counts differ by source. Board counts include physicians who are retired or not seeing patients; CMS counts only those who billed Medicare fee-for-service for at least 11 patients; a study built on the national provider file counts something else again. We print them side by side rather than pick one.
• BLS has no allergist occupation. Allergists sit in Physicians, All Other (SOC 29-1229), a catch-all holding many specialties. Wage and job figures for that group are context and are not allergist pay.
• Physician-office figures are not allergy-practice figures. BLS and Census count allergy practices inside offices of physicians (NAICS 621111), shared with every other specialty.
• Our Medicare figures cover fee-for-service Part B only. They leave out Medicare Advantage and every non-Medicare patient, which matters in a field that treats so many children and working-age adults. A fall in a code is not proof of less care. CMS hides lines with fewer than 11 patients, so test and shot counts are floors, and “none” in a county means none in CMS’s file. County totals use each provider’s listed ZIP code, and a ZIP split across counties goes to the county holding most of its land.
• Our YouTube read follows YouTube’s ranking and leans on one doctor. The 509 videos are what YouTube’s search returned for three terms (the top 200 results of each, sorted by views, with no country filter) on November 8, 2026. It is not a census of allergy video, view counts are lifetime snapshots, and we sorted 349 channels by hand from their public text without checking credentials. One doctor supplies about two thirds of the allergist views. We do not name patients, children or families, so patient and family channels are not listed by name.
• Study results come from specific settings. Each content study sampled the top results for one topic on one date and defined “medical professional” its own way, and many are small or from one country. We found no study of video before oral food challenges or allergy shots and no national survey of how many allergy practices use video.
• Allergy prevalence depends on the definition. A diagnosis reported in an interview, convincing symptoms in an online survey and a positive skin or blood test measure different things, and are printed apart here.
• Association and company figures are their own. AAFA and FARE campaign on allergy, AAAAI and ACAAI represent the field, and makers’ 10-K estimates of the number of allergists or the size of the market come from their own research. Each is labelled. Every “earliest we found” in the origins section rests on web pages, press and PubMed; annual reports for FARE, AAFA and AAAAI were not available to check.

How to cite this page

For a single figure, cite the original publisher named next to it, and link here if the verification trail is useful to your readers. Each figure has its own anchor, so you can link straight to it, for example https://www.markstudios.com/research/allergist-video-statistics#DRV-212. To cite the page as a whole:

Mark Studios. "Allergist Video Statistics." Last verified Nov 8, 2026. https://www.markstudios.com/research/allergist-video-statistics

@misc{markstudios_allergist_video_statistics_2026,
  author = {{Mark Studios}},
  title = {{Allergist Video Statistics}},
  year = {2026},
  month = nov,
  url = {https://www.markstudios.com/research/allergist-video-statistics},
  note = {Last verified 2026-11-08}
}

Our calculations and the evidence table are free to reuse with attribution and a link to this page. Each underlying figure remains the claim of its original publisher, and some publishers ask for a link when their figures are reused.

Sources

Download the evidence table (CSV)

1. European Journal of Pediatrics (Yıldırım et al.), Quality, reliability, and clinical accuracy of short-form social media videos on cow's milk protein allergy: a cross-platform content analysis. (2026-08-21). Accessed 2026-11-08.
2. Laryngoscope Investigative Otolaryngology (Kwon et al.), Quality of Allergic Rhinitis Content Across Social Media Platforms. (2026-07-02). Accessed 2026-11-08.
3. BMC Public Health (Lian et al.), Public health implications of allergic rhinitis information on YouTube and Bilibili: a cross-cultural analysis of content quality, engagement, and seasonal trends. (2026-06-11). Accessed 2026-11-08.
4. Indian Journal of Otolaryngology and Head and Neck Surgery (Kumar et al.), A Content Analysis of YouTube Videos on Allergic Rhinitis Management. (2025-04-14). Accessed 2026-11-08.
5. Allergy, Asthma & Clinical Immunology (Korkmaz et al.), The origin of YouTube videos on hereditary angioedema matters. (2025-03-20). Accessed 2026-11-08.
6. European Annals of Allergy and Clinical Immunology (Toprak et al.), Evaluation of the origin and educational quality of YouTube videos on adrenaline auto-injectors. (2024-02-20). Accessed 2026-11-08.
7. Annals of Allergy, Asthma & Immunology (Remvig et al.), YouTube as a source of (mis)information on allergic rhinitis. (2022-07-18). Accessed 2026-11-08.
8. Pediatric Allergy and Immunology (Reddy et al.), YouTube and food allergy: An appraisal of the educational quality of information. (2018-03-08). Accessed 2026-11-08.
9. Allergy and Asthma Proceedings (Gansert et al.), Scroll, like, diagnose? Evaluating mast cell activation syndrome information on TikTok. (2026-01-10). Accessed 2026-11-08.
10. JMIR Medical Education (Peters-Geven et al.), The Quality of Instructional YouTube Videos for the Administration of Intranasal Spray: Observational Study. (2020-12-31). Accessed 2026-11-08.
11. Journal of Allergy and Clinical Immunology: In Practice (Khadija et al.), Allergy Misinformation Across Social Media Platforms: Content Analysis and Public Response. (2026-02-09). Accessed 2026-11-08.
12. Turkish Archives of Pediatrics (Genis et al.), The Impact of Social Media on Parental Decision-Making in the Management of Pediatric Allergic Diseases. (2026-07-02). Accessed 2026-11-08.
13. Asia Pacific Allergy (Yuenyongviwat et al.), Utility of an educational video on epinephrine prefilled syringe usage for anaphylaxis: a randomized control trial. (2020-08-14). Accessed 2026-11-08.
14. BioMed Research International (Fernandez-Mendez et al.), Learning and Treatment of Anaphylaxis by Laypeople: A Simulation Study Using Pupilar Technology. (2017-08-02). Accessed 2026-11-08.
15. Acta Dermatovenerologica Alpina, Pannonica et Adriatica (Močnik et al.), Evaluation of adherence and knowledge retention for adrenaline autoinjector use in hymenoptera venom-allergic patients with c-KIT p.D816V. (2025-12-20). Accessed 2026-11-08.
16. Asian Pacific Journal of Allergy and Immunology (Suwan et al.), Randomized comparison of caregivers' ability to use epinephrine autoinjectors and prefilled syringes for anaphylaxis. (2018-07-10). Accessed 2026-11-08.
17. Allergy (Umasunthar et al.), Patients' ability to treat anaphylaxis using adrenaline autoinjectors: a randomized controlled trial. (2015-04-09). Accessed 2026-11-08.
18. Archives de Pediatrie (Lejtman et al.), Evaluation of a video training program's impact on primary teachers' knowledge of allergies and skills in using an adrenaline autoinjector during the 2021-2022 school year. (2024-06-10). Accessed 2026-11-08.
19. Pediatric Allergy and Immunology (Yuksel Bulut et al.), Video-based food allergy and anaphylaxis training for primary and middle school students. (2026-05-07). Accessed 2026-11-08.
20. Pediatric Allergy, Immunology, and Pulmonology (Karim et al.), Bridging Knowledge Gaps in Anaphylaxis Management Through a Video-Based Educational Tool. (2022-12-21). Accessed 2026-11-08.
21. Frontiers in Nutrition (Aytulu et al.), The evaluation of food allergy knowledge and attitude in different food sectors and the effectiveness of video-based training. (2025-03-07). Accessed 2026-11-08.
22. Public Health Nursing (Özeflanili et al.), Effectiveness of Face-to-Face and Social Media-Based Food Allergy Education for Parents: A Theory-Based Quasi-Experimental Study Using Pender's Health Promotion Model. (2026-10-30). Accessed 2026-11-08.
23. Annals of Allergy, Asthma & Immunology (Mack et al.), A counseling video with pre- and posttesting and checklist for oral immunotherapy consent improves participant knowledge. (2020-07-11). Accessed 2026-11-08.
24. Allergy and Asthma Proceedings (Winders et al.), Shifts in allergy practice in a COVID-19 world: Implications of pre-COVID-19 national health care provider and patient surveys of treatments for nasal allergies. (2021-05-26). Accessed 2026-11-08.
25. Journal of Allergy and Clinical Immunology: In Practice (Mustafa et al.), Patient Satisfaction with In-Person, Video, and Telephone Allergy/Immunology Evaluations During the COVID-19 Pandemic. (2021-02-07). Accessed 2026-11-08.
26. Journal of Allergy and Clinical Immunology: In Practice (Tsao et al.), Impact of Rapid Transition to Telemedicine-Based Delivery on Allergy/Immunology Care During COVID-19. (2021-04-25). Accessed 2026-11-08.
27. Journal of Allergy and Clinical Immunology: In Practice (Waibel et al.), Outcomes From a Regional Synchronous Tele-Allergy Service. (2018-11-06). Accessed 2026-11-08.
28. Journal of Allergy and Clinical Immunology: In Practice (Thomas et al.), Synchronous Telemedicine in Allergy: Lessons Learned and Transformation of Care During the COVID-19 Pandemic. (2020-10-23). Accessed 2026-11-08.
29. Allergy, Asthma & Clinical Immunology (Edgerley et al.), Telemedicine in allergy/immunology in the era of COVID-19: a Canadian perspective. (2022-02-23). Accessed 2026-11-08.
30. JMIR Human Factors (Lindemann et al.), TeleAllergy: Potential of Telemedicine in Management of Patients With Allergies. (2025-11-06). Accessed 2026-11-08.
31. Annals of Allergy, Asthma & Immunology (Mehta et al.), Reimbursement patterns and user experiences in pediatric allergy home telehealth. (2020-06-12). Accessed 2026-11-08.
32. Annals of Allergy, Asthma & Immunology (Portnoy et al.), Telemedicine is as effective as in-person visits for patients with asthma. (2016-09-11). Accessed 2026-11-08.
33. Telemedicine and e-Health (Inoo et al.), Retrospective Observational Study on Telemedicine in Sublingual Immunotherapy for Patients with Japanese Cedar Pollinosis and House Dust Mite Allergic Rhinitis. (2024-09-11). Accessed 2026-11-08.
34. Annals of Allergy, Asthma & Immunology (Mustafa et al.), Peanut oral immunotherapy updosing via in-office, video, and telephone encounters: Safety and caregiver satisfaction. (2026-08-29). Accessed 2026-11-08.
35. Allergy, Asthma & Clinical Immunology (Ghassemian et al.), Virtually supported penicillin allergy de-labelling during COVID-19. (2023-03-01). Accessed 2026-11-08.
36. Frontiers in Allergy (Tharpe et al.), Real-world outcomes of personalized sublingual immunotherapy for environmental allergies delivered through a telemedicine platform: a retrospective longitudinal cohort study. (2026-06-26). Accessed 2026-11-08.
37. American Board of Medical Specialties, 2025-2026 ABMS Board Certification Report (2026-09). Accessed 2026-11-08.
38. American Board of Allergy and Immunology, About ABAI (undated). Accessed 2026-11-08.
39. American Board of Allergy and Immunology, ABAI Diplomate Statistics (undated). Accessed 2026-11-08.
40. American Journal of Managed Care (Ho et al.), Geographic variability of Medicaid acceptance among allergists in the US (2024-08). Accessed 2026-11-08.
41. Association of American Medical Colleges, Active Physicians by Age and Specialty, 2021 (2022 Physician Specialty Data Report, Table 1.4) (2022). Accessed 2026-11-08.
42. Florida Department of Health, Florida Physician Workforce 2025 Annual Report (2025-11-01). Accessed 2026-11-08.
43. Accreditation Council for Graduate Medical Education, ACGME Data Resource Book, Academic Year 2024-2025 (2025). Accessed 2026-11-08.
44. Accreditation Council for Graduate Medical Education, ACGME Data Resource Book, Academic Year 2015-2016 (2016). Accessed 2026-11-08.
45. American Board of Allergy and Immunology, ABAI Examination Statistics (undated). Accessed 2026-11-08.
46. Annals of Allergy, Asthma & Immunology (King et al.), Geospatial and insurance barriers to allergist access across the Midwest (2026-10). Accessed 2026-11-08.
47. Journal of Asthma and Allergy (Bohnhoff et al.), Access to Pediatric Asthma Specialty Care: A Survey and Geospatial Analysis Across a Rural State (2025-03). Accessed 2026-11-08.
48. American College of Allergy, Asthma & Immunology (association), reporting an American Medical Association survey, Allergy telehealth survey results are here (2022). Accessed 2026-11-08.
49. American Medical Association, for the American College of Allergy, Asthma & Immunology (association), 2021 National Telehealth Survey Report - Allergy/Immunology (2022). Accessed 2026-11-08.
50. Annals of Allergy, Asthma & Immunology (Meadows et al.), Challenges in the management of hereditary angioedema in urban and rural settings: Results of a United States survey (2023-06). Accessed 2026-11-08.
51. Journal of Allergy and Clinical Immunology: In Practice (Kahwash et al.), Allergy/Immunology Trainee Experiences During the COVID-19 Pandemic: AAAAI Work Group Report of the Fellows-in-Training Committee (2021-01). Accessed 2026-11-08.
52. Annals of Allergy, Asthma & Immunology (Sivam et al.), Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey (2019-06). Accessed 2026-11-08.
53. Annals of Allergy, Asthma & Immunology (Tucker et al.), Perception and practice of sublingual immunotherapy among practicing allergists (2008-10). Accessed 2026-11-08.
54. Journal of Allergy and Clinical Immunology: In Practice (Anagnostou et al.), Food Oral Immunotherapy: A Survey Among US Practicing Allergists Conducted as a AAAAI Leadership Institute Project and Work Group Report (2023-08). Accessed 2026-11-08.
55. Journal of Allergy and Clinical Immunology: In Practice (Greenhawt and Vickery), Allergist-reported trends in the practice of food allergen oral immunotherapy (2015-01). Accessed 2026-11-08.
56. Waypoint Capital (press release via Business Wire), Waypoint Capital Acquires Majority Stake in Allergy Partners (2021-12-20). Accessed 2026-11-08.
57. Allergy Partners (company website), About Us (undated). Accessed 2026-11-08.
58. SC&H Capital (investment bank, adviser to the seller, press release), SC&H Capital Advises Allergy & Asthma Consultants in Sale to Family Allergy & Asthma (2021-09-07). Accessed 2026-11-08.
59. FOCUS Investment Banking (adviser that sells M&A services to medical practices), Healthcare Industry: ENT & Allergy 2024 Update: Conservative Pace Continues (2024-04). Accessed 2026-11-08.
60. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider (2024 data) (2026-05-21). Accessed 2026-11-08.
61. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider (2019 data) (2025-03-26). Accessed 2026-11-08.
62. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider (2024 data) (2026-05-21). Accessed 2026-11-08.
63. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider (2019 data) (2025-03-26). Accessed 2026-11-08.
64. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider (2024 data) (2026-05-21). Accessed 2026-11-08.
65. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider (2024 data) (2026-05-21). Accessed 2026-11-08.
66. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider (2024 data) (2026-05-21). Accessed 2026-11-08.
67. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider (2024 data) (2026-05-21). Accessed 2026-11-08.
68. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
69. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
70. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
71. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
72. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
73. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
74. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
75. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
76. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
77. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
78. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
79. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider and Service (2019 data) (2025-03-26). Accessed 2026-11-08.
80. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
81. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
82. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
83. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
84. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
85. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
86. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
87. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
88. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
89. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
90. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
91. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
92. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
93. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
94. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Provider and Service (2019 data) (2025-03-26). Accessed 2026-11-08.
95. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2024 data) (2026-05-21). Accessed 2026-11-08.
96. Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners - by Geography and Service (2019 data) (2023-05-10). Accessed 2026-11-08.
97. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
98. U.S. Bureau of Labor Statistics, Occupational Outlook Handbook: Physicians and Surgeons (2026-08-27). Accessed 2026-11-08.
99. U.S. Bureau of Labor Statistics, Employment Projections Table 1.2: Occupational projections, 2025-35, and worker characteristics, 2025 (2026-08-27). Accessed 2026-11-08.
100. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
101. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
102. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
103. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
104. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
105. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
106. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
107. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
108. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
109. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
110. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
111. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
112. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
113. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
114. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
115. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
116. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
117. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
118. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
119. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
120. U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2025 estimates (2026-05-15). Accessed 2026-11-08.
121. U.S. Bureau of Labor Statistics, QCEW open data, 2025 annual averages, industry 621111 (2026-09-03). Accessed 2026-11-08.
122. U.S. Bureau of Labor Statistics, QCEW open data, 2019 annual averages, industry 621111 (2020-09-02). Accessed 2026-11-08.
123. U.S. Census Bureau, County Business Patterns 2023 (Census Data API, cbp) (2025-06-26). Accessed 2026-11-08.
124. U.S. Census Bureau, Nonemployer Statistics 2024 (Census Data API, nonemp) (2026-06-25). Accessed 2026-11-08.
125. U.S. Census Bureau, Nonemployer Statistics 2023 (Census Data API, nonemp) (2025-06-26). Accessed 2026-11-08.
126. U.S. Census Bureau, County Business Patterns 2023 (Census Data API, cbp) (2025-06-26). Accessed 2026-11-08.
127. U.S. Census Bureau, County Business Patterns 2023 (Census Data API, cbp) (2025-06-26). Accessed 2026-11-08.
128. U.S. Census Bureau, 2022 Economic Census: Selected Statistics by Industry (ecnbasic) (2025-01-23). Accessed 2026-11-08.
129. U.S. Census Bureau, 2022 Economic Census: Industry by Products (ecnnapcsind) (2024-12-12). Accessed 2026-11-08.
130. U.S. Census Bureau, 2022 Economic Census: Revenue by Type of Payer (ecntypepayer) (2025-01-23). Accessed 2026-11-08.
131. U.S. Census Bureau, 2022 Economic Census: Telemedicine Services by Industry (ecntelemeds) (2025-01-23). Accessed 2026-11-08.
132. U.S. Census Bureau, Annual Integrated Economic Survey: Detailed Operating Expenses: 2024 (aiesexp02) (2026-05-28). Accessed 2026-11-08.
133. U.S. Census Bureau, Annual Integrated Economic Survey: Detailed Operating Expenses: 2023 (aiesexp02) (2025-06). Accessed 2026-11-08.
134. U.S. Census Bureau, 2022 Economic Census: Concentration by Firm Size (ecnsize) (2024-11-27). Accessed 2026-11-08.
135. National Center for Health Statistics, CDC, Diagnosed Allergic Conditions in Adults: United States, 2024 (NCHS Data Brief No. 545) (2026-01-08). Accessed 2026-11-08.
136. National Center for Health Statistics, CDC, Diagnosed Allergic Conditions in Children Ages 0-17: United States, 2024 (NCHS Data Brief No. 546) (2026-01-08). Accessed 2026-11-08.
137. National Center for Health Statistics, CDC, Diagnosed Allergic Conditions in Adults: United States, 2021 (NCHS Data Brief No. 460) (2023-01). Accessed 2026-11-08.
138. National Center for Health Statistics, CDC, Diagnosed Allergic Conditions in Children Aged 0-17 Years: United States, 2021 (NCHS Data Brief No. 459) (2023-01). Accessed 2026-11-08.
139. JAMA Network Open (Gupta et al.), Prevalence and Severity of Food Allergies Among US Adults (2019-01-04). Accessed 2026-11-08.
140. Pediatrics (Gupta et al.), The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States (2018-12). Accessed 2026-11-08.
141. Journal of Allergy and Clinical Immunology (Liu et al.), National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006 (2010-10). Accessed 2026-11-08.
142. National Institute of Allergy and Infectious Diseases, NIH, Food Allergy (NIAID) (2025-08-13). Accessed 2026-11-08.
143. Food Allergy Research & Education (FARE), advocacy group, Facts and Statistics (FARE) (undated). Accessed 2026-11-08.
144. Asthma and Allergy Foundation of America (AAFA), advocacy group, Allergy Facts, Figures and Stats (AAFA) (2026-04). Accessed 2026-11-08.
145. Journal of Allergy and Clinical Immunology (Salo et al.), Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006 (2014-08). Accessed 2026-11-08.
146. Journal of Allergy and Clinical Immunology (Arbes et al.), Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey (2005-08). Accessed 2026-11-08.
147. National Center for Health Statistics, CDC, Trends in Allergic Conditions Among Children: United States, 1997-2011 (NCHS Data Brief No. 121) (2013-05). Accessed 2026-11-08.
148. Pediatrics (Gabryszewski et al.), Guidelines for Early Food Introduction and Patterns of Food Allergy (2025-11-01). Accessed 2026-11-08.
149. Centers for Disease Control and Prevention, Most Recent Asthma Data (2026-10-06). Accessed 2026-11-08.
150. National Center for Health Statistics, CDC, NHIS Adult Summary Health Statistics (data.cdc.gov dataset 25m4-6qqq) (2026-08-27). Accessed 2026-11-08.
151. National Center for Health Statistics, CDC, NHIS Adult Summary Health Statistics (data.cdc.gov dataset 25m4-6qqq) (2026-08-27). Accessed 2026-11-08.
152. National Center for Health Statistics, CDC, NHIS Child Summary Health Statistics (data.cdc.gov dataset wxz7-ekz9) (2026-08-27). Accessed 2026-11-08.
153. National Center for Health Statistics, CDC, NHIS Child Summary Health Statistics (data.cdc.gov dataset wxz7-ekz9) (2026-08-27). Accessed 2026-11-08.
154. Centers for Disease Control and Prevention, PLACES: Local Data for Better Health, County Data, 2025 release (2025-12-04). Accessed 2026-11-08.
155. Centers for Disease Control and Prevention, PLACES: Local Data for Better Health, County Data, 2025 release (2025-12-04). Accessed 2026-11-08.
156. Centers for Disease Control and Prevention, PLACES: Local Data for Better Health, County Data, 2025 release (2025-12-04). Accessed 2026-11-08.
157. Centers for Disease Control and Prevention, PLACES: Local Data for Better Health, County Data, 2025 release (2025-12-04). Accessed 2026-11-08.
158. Centers for Disease Control and Prevention, PLACES: Local Data for Better Health, County Data, 2025 release (2025-12-04). Accessed 2026-11-08.
159. Journal of Allergy and Clinical Immunology (Wood et al.), Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States (2014-02). Accessed 2026-11-08.
160. Journal of Allergy and Clinical Immunology: In Practice (Motosue et al.), Increasing Emergency Department Visits for Anaphylaxis, 2005-2014 (2017-01). Accessed 2026-11-08.
161. Pediatric Allergy and Immunology (Motosue et al.), National trends in emergency department visits and hospitalizations for food-induced anaphylaxis in US children (2018-08). Accessed 2026-11-08.
162. Journal of Allergy and Clinical Immunology: In Practice (Robinson et al.), Trends in US Emergency Department Visits for Anaphylaxis Among Infants and Toddlers: 2006-2015 (2021-05). Accessed 2026-11-08.
163. Journal of Allergy and Clinical Immunology (Ma et al.), Case fatality and population mortality associated with anaphylaxis in the United States (2014-04). Accessed 2026-11-08.
164. Annals of Allergy, Asthma & Immunology (Shrestha et al.), Trends in hospitalizations related to anaphylaxis, angioedema, and urticaria in the United States (2019-04). Accessed 2026-11-08.
165. Journal of Allergy and Clinical Immunology (Jerschow et al.), Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations (2014-12). Accessed 2026-11-08.
166. Journal of Allergy and Clinical Immunology: In Practice (Motosue et al.), Temporal Trends in Epinephrine Dispensing and Allergy/Immunology Follow-up Among Emergency Department Anaphylaxis Patients in the United States, 2005-2014 (2017-09). Accessed 2026-11-08.
167. Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. Form 10-K for fiscal year 2025 (2026-02-04). Accessed 2026-11-08.
168. ARS Pharmaceuticals, Inc., ARS Pharmaceuticals, Inc. Form 10-K for fiscal year 2025 (2026-03-09). Accessed 2026-11-08.
169. DBV Technologies S.A., DBV Technologies S.A. Form 10-K for fiscal year 2025 (2026-03-26). Accessed 2026-11-08.
170. Aimmune Therapeutics, Inc., Aimmune Therapeutics, Inc. Form 10-K for fiscal year 2019 (2020-02-27). Accessed 2026-11-08.
171. OptiNose, Inc., OptiNose, Inc. Form 10-K for fiscal year 2024 (2025-03-26). Accessed 2026-11-08.
172. Sanofi, Sanofi Annual Report on Form 20-F for fiscal year 2025 (2026-02-17). Accessed 2026-11-08.
173. QHSLab, Inc., QHSLab, Inc. Form 10-K for fiscal year 2025 (2026-03-30). Accessed 2026-11-08.
174. QHSLab, Inc., QHSLab, Inc. Form 10-K for fiscal year 2024 (2025-03-28). Accessed 2026-11-08.
175. Viatris Inc., Viatris Inc. Form 10-K for fiscal year 2025 (2026-02-26). Accessed 2026-11-08.
176. Mylan N.V., Mylan N.V. Form 10-K for fiscal year 2016 (2017-03-01). Accessed 2026-11-08.
177. Mylan N.V., Mylan N.V. Form 10-K for fiscal year 2015 (2016-02-16). Accessed 2026-11-08.
178. Mylan N.V., Mylan N.V. Form 10-K for fiscal year 2017 (2018-03-01). Accessed 2026-11-08.
179. Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited Form 10-K for fiscal year 2025 (2026-02-03). Accessed 2026-11-08.
180. Mylan Inc., Mylan Inc. Form 10-K for fiscal year 2011 (2012-02-21). Accessed 2026-11-08.
181. Aquestive Therapeutics, Inc., Aquestive Therapeutics, Inc. Form 10-K for fiscal year 2025 (2026-03-04). Accessed 2026-11-08.
182. Evommune, Inc., Evommune, Inc. Form 10-K for fiscal year 2025 (2026-03-05). Accessed 2026-11-08.
183. Novartis AG, Novartis AG Annual Report on Form 20-F for fiscal year 2025 (2026-02-04). Accessed 2026-11-08.
184. Thermo Fisher Scientific Inc., Thermo Fisher Scientific Inc. Form 10-K for fiscal year 2025 (2026-02-26). Accessed 2026-11-08.
185. Thermo Fisher Scientific Inc., Thermo Fisher Scientific Inc. Form 10-K for fiscal year 2021 (2022-02-24). Accessed 2026-11-08.
186. LifeMD, Inc., LifeMD, Inc. Form 10-K for fiscal year 2022 (2023-03-22). Accessed 2026-11-08.
187. U.S. Food and Drug Administration, Injectable Allergen Extracts- Standardized (2019-06-04). Accessed 2026-11-08.
188. U.S. Food and Drug Administration (rule text via eCFR, Office of the Federal Register), 21 CFR Part 680 -- Additional Standards for Miscellaneous Products (2026-11-08). Accessed 2026-11-08.
189. U.S. Food and Drug Administration, Allergenics (2026-09-08). Accessed 2026-11-08.
190. U.S. Congress (Public Law 108-282, via govinfo.gov), Public Law 108-282 (2004-08-02). Accessed 2026-11-08.
191. U.S. Congress (Public Law 117-11, via govinfo.gov), Public Law 117-11 (2021-04-23). Accessed 2026-11-08.
192. U.S. Food and Drug Administration, BLA approval letter, Peanut (Arachis hypogaea) Allergen Powder-dnfp (PALFORZIA) (2020-01-31). Accessed 2026-11-08.
193. U.S. Food and Drug Administration, PALFORZIA (2026-11-08). Accessed 2026-11-08.
194. U.S. Food and Drug Administration, FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure (2024-02-16). Accessed 2026-11-08.
195. U.S. Food and Drug Administration, FDA Approves First Nasal Spray for Treatment of Anaphylaxis (2024-08-09). Accessed 2026-11-08.
196. U.S. Food and Drug Administration (rule text via eCFR, Office of the Federal Register), 21 CFR 202.1 -- Prescription-drug advertisements (2026-11-08). Accessed 2026-11-08.
197. U.S. Food and Drug Administration (Federal Register), Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format (2023-11-21). Accessed 2026-11-08.
198. U.S. Department of Health and Human Services (rule text via eCFR, Office of the Federal Register), 45 CFR 102.3 -- Penalty adjustment and table (2026-11-08). Accessed 2026-11-08.
199. U.S. Food and Drug Administration, Close-out letter to kaleo, Inc., NDA 201739 AUVI-Q, MA 1021 (2024-07-17). Accessed 2026-11-08.
200. U.S. Food and Drug Administration, Untitled letter to kaleo, Inc., NDA 201739 AUVI-Q, MA 1021 (2024-07-17). Accessed 2026-11-08.
201. U.S. Food and Drug Administration, Untitled letter to ARS Pharmaceutical Operations, Inc., NDA 214697 NEFFY, MA 250 (2026-01-23). Accessed 2026-11-08.
202. U.S. Food and Drug Administration, Untitled letter to ARS Pharmaceutical Operations, Inc., NDA 214697 NEFFY, MA 136 (2025-09-09). Accessed 2026-11-08.
203. U.S. Food and Drug Administration, Close-out letter to ARS Pharmaceutical Operations, Inc., NDA 214697 NEFFY, MA 250 (2026-01-23). Accessed 2026-11-08.
204. U.S. Food and Drug Administration, Untitled letter to AstraZeneca Pharmaceuticals LP, BLA 761070 FASENRA, MA 1157 (2025-09-09). Accessed 2026-11-08.
205. U.S. Food and Drug Administration, FDA Launches Crackdown on Deceptive Drug Advertising (2025-09-09). Accessed 2026-11-08.
206. The Florida Legislature, The 2026 Florida Statutes, 1002.20 K-12 student and parent rights (2026). Accessed 2026-11-08.
207. The Florida Legislature, The 2026 Florida Statutes, 381.88 Emergency allergy treatment (2026). Accessed 2026-11-08.
208. The Florida Legislature, The 2026 Florida Statutes, 381.885 Epinephrine auto-injectors; emergency administration (2026). Accessed 2026-11-08.
209. The Florida Legislature, The 2026 Florida Statutes, 458.331 Grounds for disciplinary action; action by the board and department (2026). Accessed 2026-11-08.
210. The Florida Legislature, The 2026 Florida Statutes, 456.072 Grounds for discipline; penalties; enforcement (2026). Accessed 2026-11-08.
211. Florida Department of State (Florida Administrative Code), Board of Medicine rule, 64B8-11.001 Advertising (rule text) (2026-03-19). Accessed 2026-11-08.
212. The Florida Legislature, The 2026 Florida Statutes, 456.47 Use of telehealth to provide services (2026). Accessed 2026-11-08.
213. Federal Trade Commission (rule text via eCFR, Office of the Federal Register), 16 CFR Part 255 -- Guides Concerning Use of Endorsements and Testimonials in Advertising (2023-07-26). Accessed 2026-11-08.
214. Federal Trade Commission (Federal Register), Trade Regulation Rule on the Use of Consumer Reviews and Testimonials (Federal Register, 2024-08-22) (2024-08-22). Accessed 2026-11-08.
215. Federal Trade Commission (rule text via eCFR, Office of the Federal Register), 16 CFR 1.98 -- Adjustment of civil monetary penalty amounts (2025-01-17). Accessed 2026-11-08.
216. U.S. Department of Health and Human Services (rule text via eCFR, Office of the Federal Register), 45 CFR 164.501 -- Definitions (2026-11-08). Accessed 2026-11-08.
217. U.S. Department of Health and Human Services (rule text via eCFR, Office of the Federal Register), 45 CFR 164.508 -- Uses and disclosures for which an authorization is required (2026-11-08). Accessed 2026-11-08.
218. U.S. Department of Health and Human Services (rule text via eCFR, Office of the Federal Register), 45 CFR 164.514 -- Other requirements relating to uses and disclosures of protected health information (2026-11-08). Accessed 2026-11-08.
219. U.S. Department of Health and Human Services, Office for Civil Rights, Physical therapy provider settles violations that it impermissibly disclosed patient information (2016-02-12). Accessed 2026-11-08.
220. Centers for Medicare & Medicaid Services, Telehealth FAQ (updated 10/8/26) (2026-10-08). Accessed 2026-11-08.
221. CDC National Center for Health Statistics, NCHS Data Brief No. 545: Diagnosed Allergic Conditions in Adults: United States, 2024 (2026-01). Accessed 2026-11-08.
222. CDC National Center for Health Statistics, NCHS Data Brief No. 546: Diagnosed Allergic Conditions in Children Ages 0-17: United States, 2024 (2026-01-08). Accessed 2026-11-08.
223. National Institute of Allergy and Infectious Diseases (NIH), NIAID Fact Sheet: Asthma and Allergy Statistics (Undated fact sheet; earliest capture 1997-02-22). Accessed 2026-11-08.
224. Journal of Allergy and Clinical Immunology (Gergen et al., National Center for Health Statistics and FDA), The prevalence of allergic skin test reactivity to eight common aeroallergens in the U.S. population (1987-11). Accessed 2026-11-08.
225. National Institute of Allergy and Infectious Diseases (NIH), NIAID Fact Sheet: Asthma and Allergy Statistics (January 2000) (2000-01). Accessed 2026-11-08.
226. National Institute of Allergy and Infectious Diseases (NIH), NIAID Fact Sheet: Allergy Statistics (January 2002) (2002-01). Accessed 2026-11-08.
227. Asthma and Allergy Foundation of America (patient advocacy group), Allergy Facts and Figures (Undated; captured 2005-01-16). Accessed 2026-11-08.
228. Centers for Disease Control and Prevention, Gateway to Health Communication: Allergies (resources for entertainment education content developers) (2011-02-02). Accessed 2026-11-08.
229. American College of Allergy, Asthma and Immunology (association of allergists), Allergy Facts (Page reviewed 2023-06-28). Accessed 2026-11-08.
230. Asthma and Allergy Foundation of America (patient advocacy group), Allergy Facts (Undated (read 2026-11-08)). Accessed 2026-11-08.
231. CDC National Center for Health Statistics, NCHS Data Brief No. 10: Food Allergy Among U.S. Children: Trends in Prevalence and Hospitalizations (2008-10). Accessed 2026-11-08.
232. Pediatrics (Gupta et al., Northwestern University and Children's Memorial Hospital), The prevalence, severity, and distribution of childhood food allergy in the United States (2011-07). Accessed 2026-11-08.
233. Food Allergy Initiative (advocacy funder of the study), press release via PR Newswire, 1 in 13 U.S. Children Suffer from Food Allergies, Study Finds (2011-06-20). Accessed 2026-11-08.
234. Children's Memorial Hospital (news release via News-Medical), Study: 1 in 13 children suffer from food allergies (2011-06-21). Accessed 2026-11-08.
235. EyeView Digital (video production and testing vendor; sold the videos it tested), EyeView - The new "Conversion" game (2008-12-04). Accessed 2026-11-08.
236. EyeView Digital (video production and testing vendor; sold the videos it tested), UMOO - a prime beef example of EyeView's success (2009-02-10). Accessed 2026-11-08.
237. EyeView Digital (video production and testing vendor; sold the videos it tested), Making Video Accountable (EyeView white paper) (2010). Accessed 2026-11-08.
238. Unbounce (landing-page software seller), The benefits of using video on landing pages (2010-08). Accessed 2026-11-08.
239. Practice Builders (healthcare marketing company; sells video to practices), 5 Video Marketing Ideas for Your Healthcare Practice (Undated (read 2026-11-08)). Accessed 2026-11-08.
240. Webtonic (marketing agency selling to medical practices), Landing Pages & CRO Performance in Allergy & Immunology: 88+ Stats for 2026 (2026-07-20). Accessed 2026-11-08.
241. Unbounce (landing-page software seller; analysis of its own customers' pages), Video on landing pages means more conversions, right? Wrong. Here's why (2021-08-26). Accessed 2026-11-08.
242. National Academy on an Aging Society, Chronic Conditions: A Challenge for the 21st Century (1999-11). Accessed 2026-11-08.
243. American Council of Learned Societies (fellowship abstract by Gregg Mitman), Gregg Mitman, ACLS Fellowship Program 2004: Breathing Space (2004). Accessed 2026-11-08.
244. American College of Allergy, Asthma and Immunology (association of allergists), Allergy Facts (2018-01-09). Accessed 2026-11-08.
245. Asthma and Allergy Foundation of America (patient advocacy group), Allergy Facts (Undated; captured 2019-01-02). Accessed 2026-11-08.
246. Ambetter Health (health insurer, Centene), Allergies: Disease Management & Preventive Care (Undated (read 2026-11-08)). Accessed 2026-11-08.
247. Reuters Health (news report carried by Fox News) on Clark et al., J Allergy Clin Immunol 2011, Study finds high rate of ER trips for food allergies (2010-12-29). Accessed 2026-11-08.
248. Allergy and Asthma Proceedings (Clark et al., Weill Cornell), Favorable trends in the frequency of U.S. emergency department visits for food allergy, 2001-2009 (2013-09). Accessed 2026-11-08.
249. Food Allergy & Anaphylaxis Network (advocacy group; its site foodallergy.org is now FARE's), Food Allergy Facts and Statistics for the U.S. (Undated; captured 2012-01-14). Accessed 2026-11-08.
250. Office of the Governor of Michigan (proclamation quoting FARE), May 9-15, 2021: Food Allergy Awareness Week (2021-05-09). Accessed 2026-11-08.
251. Food Allergy Research & Education (advocacy group that funds food allergy research), Facts and Statistics (Undated; captured 2024-02-21). Accessed 2026-11-08.
252. Food Allergy Research & Education (advocacy group that funds food allergy research), Statement by Sung Poblete, RN, PhD, CEO of FARE, regarding the 33 million individuals in the United States with life-threatening food allergies (2023-08-10). Accessed 2026-11-08.
253. Food Allergy Research & Education (advocacy group that funds food allergy research), New prevalence numbers demand aggressive call to action (2019-02-12). Accessed 2026-11-08.

Update policy and change log

We re-verify every figure quarterly and when a major source publishes a new edition. The next scheduled review is February 2027. Corrections go to contact@markstudios.com.

• Nov 8, 2026: First published with 698 figures from 75 publishers, each checked against its original source.
• Nov 9, 2026: Removed the National Resident Matching Program (NRMP) fellowship match figures; NRMP’s reports don’t permit use of their data with AI tools without written consent.